Cover Document
Cover Document - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Jan. 31, 2023 | Jun. 30, 2022 | |
Cover Page [Abstract] | |||
Entity File Number | 1-10864 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Year Focus | 2022 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Document Transition Report | false | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 41-1321939 | ||
Entity Address, Address Line One | UnitedHealth Group Center | ||
Entity Address, Address Line Two | 9900 Bren Road East | ||
Entity Address, City or Town | Minnetonka, | ||
Entity Address, State or Province | MN | ||
Entity Address, Postal Zip Code | 55343 | ||
City Area Code | 952 | ||
Local Phone Number | 936-1300 | ||
Title of 12(b) Security | Common Stock, $.01 par value | ||
Trading Symbol | UNH | ||
Security Exchange Name | NYSE | ||
Well known seasoned issuer | Yes | ||
Entity Voluntary Filers | No | ||
Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Public Float | $ 479,550,880,245 | ||
Entity Common Stock, Shares Outstanding | 932,846,602 | ||
Documents Incorporated by Reference | The information required by Part III of this report, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement relating to its 2023 Annual Meeting of Shareholders. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. | ||
Entity Registrant Name | UnitedHealth Group Incorporated | ||
Entitiy Central Index Key | 0000731766 | ||
ICFR Auditor Attestation Flag | true |
Auditor Information
Auditor Information | 12 Months Ended |
Dec. 31, 2022 | |
Auditor Information [Abstract] | |
Auditor Name | DELOITTE & TOUCHE LLP |
Auditor Firm ID | 34 |
Auditor Location | Minneapolis, Minnesota |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 23,365 | $ 21,375 |
Short-term investments | 4,546 | 2,532 |
Accounts receivable, net of allowances of $877 and $954 | 17,681 | 14,216 |
Other current receivables, net of allowances of $1,433 and $993 | 12,769 | 13,866 |
Assets under management | 4,087 | 4,449 |
Prepaid expenses and other current assets | 6,621 | 5,320 |
Total current assets | 69,069 | 61,758 |
Long-term investments | 43,728 | 43,114 |
Property, equipment and capitalized software, net of accumulated depreciation and amortization of $6,930 and $5,992 | 10,128 | 8,969 |
Goodwill | 93,352 | 75,795 |
Other intangible assets, net of accumulated amortization of $6,137 and $5,636 | 14,401 | 10,044 |
Other assets | 15,027 | 12,526 |
Total assets | 245,705 | 212,206 |
Current liabilities: | ||
Medical costs payable | 29,056 | 24,483 |
Accounts payable and accrued liabilities | 27,715 | 24,643 |
Short-term borrowings and current maturities of long-term debt | 3,110 | 3,620 |
Unearned revenues | 3,075 | 2,571 |
Other current liabilities | 26,281 | 22,975 |
Total current liabilities | 89,237 | 78,292 |
Long-term debt, less current maturities | 54,513 | 42,383 |
Deferred income taxes | 2,769 | 3,265 |
Other liabilities | 12,839 | 11,787 |
Total liabilities | 159,358 | 135,727 |
Commitments and contingencies (Note 12) | ||
Redeemable noncontrolling interests | 4,897 | 1,434 |
Equity: | ||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding | 9 | 10 |
Retained earnings | 86,156 | 77,134 |
Accumulated other comprehensive loss | (8,393) | (5,384) |
Nonredeemable noncontrolling interests | 3,678 | 3,285 |
Total equity | 81,450 | 75,045 |
Total liabilities, redeemable noncontrolling interests and equity | $ 245,705 | $ 212,206 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 934 | 941 |
Common Stock, Shares, Outstanding | 934 | 941 |
Consolidated Balance Sheet (Par
Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Allowance for doubtful accounts, accounts receivable | $ 877 | $ 954 |
Allowance for doubtful accounts, other receivables | 1,433 | 993 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 6,930 | 5,992 |
Finite-lived Intangible Assets, Accumulated Amortization | $ 6,137 | $ 5,636 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Premiums | $ 257,157 | $ 226,233 | $ 201,478 |
Investment and other income | 2,030 | 2,324 | 1,502 |
Total revenues | 324,162 | 287,597 | 257,141 |
Operating costs: | |||
Medical costs | 210,842 | 186,911 | 159,396 |
Operating costs | 47,782 | 42,579 | 41,704 |
Cost of products sold | 33,703 | 31,034 | 30,745 |
Depreciation and amortization | 3,400 | 3,103 | 2,891 |
Total operating costs | 295,727 | 263,627 | 234,736 |
Earnings from operations | 28,435 | 23,970 | 22,405 |
Interest expense | (2,092) | (1,660) | (1,663) |
Earnings before income taxes | 26,343 | 22,310 | 20,742 |
Provision for income taxes | (5,704) | (4,578) | (4,973) |
Net earnings | 20,639 | 17,732 | 15,769 |
Earnings attributable to noncontrolling interests | (519) | (447) | (366) |
Net earnings attributable to UnitedHealth Group common shareholders | $ 20,120 | $ 17,285 | $ 15,403 |
Earnings per share attributable to UnitedHealth Group common shareholders: | |||
Basic | $ 21.47 | $ 18.33 | $ 16.23 |
Diluted | $ 21.18 | $ 18.08 | $ 16.03 |
Basic weighted-average number of common shares outstanding | 937 | 943 | 949 |
Dilutive effect of common share equivalents | 13 | 13 | 12 |
Diluted weighted-average number of common shares outstanding | 950 | 956 | 961 |
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 3 | 1 | 8 |
Products | |||
Revenue from Products and Services | $ 37,424 | $ 34,437 | $ 34,145 |
Services | |||
Revenue from Products and Services | $ 27,551 | $ 24,603 | $ 20,016 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Net earnings | $ 20,639 | $ 17,732 | $ 15,769 |
Other comprehensive loss: | |||
Gross unrealized (losses) gains on investment securities during the period | (4,292) | (1,028) | 1,058 |
Income tax effect | 984 | 248 | (253) |
Total unrealized (losses) gains, net of tax | (3,308) | (780) | 805 |
Gross reclassification adjustment for net realized losses (gains) included in net earnings | 139 | (173) | (75) |
Income tax effect | (32) | 40 | 17 |
Total reclassification adjustment, net of tax | 107 | (133) | (58) |
Total foreign currency translation gains (losses) | 192 | (657) | (983) |
Other comprehensive loss | (3,009) | (1,570) | (236) |
Comprehensive income | 17,630 | 16,162 | 15,533 |
Comprehensive income attributable to noncontrolling interests | (519) | (447) | (366) |
Comprehensive income attributable to UnitedHealth Group common shareholders | $ 17,111 | $ 15,715 | $ 15,167 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Net Unrealized Gains (Losses) on Investments [Member] | Foreign Currency Translation (Losses) Gains [Member] | Noncontrolling Interest |
Balance at Dec. 31, 2019 | $ 60,436 | $ 9 | $ 7 | $ 61,178 | $ 589 | $ (4,167) | $ 2,820 |
Balance (Accounting Standards Update 2016-13) at Dec. 31, 2019 | (28) | (28) | |||||
Balance (in shares) at Dec. 31, 2019 | 948 | ||||||
Net earnings attributable to UnitedHealth Group common shareholders | 15,403 | 15,403 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 254 | ||||||
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 15,657 | ||||||
Other comprehensive (loss) gains | (236) | 747 | (983) | ||||
Issuances of common stock, and related tax effects (in shares) | 12 | ||||||
Issuances of common stock, and related tax effects | 1,120 | $ 1 | 1,119 | ||||
Share-based compensation | 647 | 647 | |||||
Common share repurchases (in shares) | (14) | ||||||
Common share repurchases | (4,250) | $ 0 | (1,576) | (2,674) | |||
Cash dividends paid on common shares ($6.40 per share, $5.60 per share and $4.83 per share for the years ended December 31, 2022, 2021 and 2020, respectively) | (4,584) | (4,584) | |||||
Redeemable noncontrolling interests fair value and other adjustments | (197) | (197) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 40 | 40 | |||||
Distributions to nonredeemable noncontrolling interests | (277) | (277) | |||||
Balance at Dec. 31, 2020 | 68,328 | $ 10 | 0 | 69,295 | 1,336 | (5,150) | 2,837 |
Balance (in shares) at Dec. 31, 2020 | 946 | ||||||
Net earnings attributable to UnitedHealth Group common shareholders | 17,285 | 17,285 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 360 | ||||||
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 17,645 | ||||||
Other comprehensive (loss) gains | (1,570) | (913) | (657) | ||||
Issuances of common stock, and related tax effects (in shares) | 8 | ||||||
Issuances of common stock, and related tax effects | 1,100 | $ 0 | 1,100 | ||||
Share-based compensation | $ 729 | 729 | |||||
Common share repurchases (in shares) | (13) | (13) | |||||
Common share repurchases | $ (5,000) | $ 0 | (940) | (4,060) | |||
Cash dividends paid on common shares ($6.40 per share, $5.60 per share and $4.83 per share for the years ended December 31, 2022, 2021 and 2020, respectively) | (5,280) | (5,280) | |||||
Redeemable noncontrolling interests fair value and other adjustments | (995) | (889) | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 407 | 407 | |||||
Distributions to nonredeemable noncontrolling interests | (319) | (319) | |||||
Balance at Dec. 31, 2021 | $ 75,045 | $ 10 | 0 | 77,134 | 423 | (5,807) | 3,285 |
Balance (in shares) at Dec. 31, 2021 | 941 | 941 | |||||
Net earnings attributable to UnitedHealth Group common shareholders | $ 20,120 | 20,120 | |||||
Net earnings attributable to nonredeemable noncontrolling interest | 406 | ||||||
Net earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest | 20,526 | ||||||
Other comprehensive (loss) gains | (3,009) | (3,201) | 192 | ||||
Issuances of common stock, and related tax effects (in shares) | 7 | ||||||
Issuances of common stock, and related tax effects | 903 | $ 0 | 903 | ||||
Share-based compensation | $ 875 | 875 | |||||
Common share repurchases (in shares) | (14) | (14) | |||||
Common share repurchases | $ (7,000) | $ (1) | (1,892) | (5,107) | |||
Cash dividends paid on common shares ($6.40 per share, $5.60 per share and $4.83 per share for the years ended December 31, 2022, 2021 and 2020, respectively) | (5,991) | (5,991) | |||||
Redeemable noncontrolling interests fair value and other adjustments | 114 | 114 | |||||
Acquisition and other adjustments of nonredeemable noncontrolling interests | 374 | 374 | |||||
Distributions to nonredeemable noncontrolling interests | (387) | (387) | |||||
Balance at Dec. 31, 2022 | $ 81,450 | $ 9 | $ 0 | $ 86,156 | $ (2,778) | $ (5,615) | $ 3,678 |
Balance (in shares) at Dec. 31, 2022 | 934 | 934 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Equity (Parenthetical) - $ / shares | 12 Months Ended | ||||||
Dec. 13, 2022 | Sep. 20, 2022 | Jun. 28, 2022 | Mar. 22, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | |||||||
Cash dividends per common share | $ 1.65 | $ 1.65 | $ 1.65 | $ 1.45 | $ 6.40 | $ 5.60 | $ 4.83 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating activities | |||
Net earnings | $ 20,639 | $ 17,732 | $ 15,769 |
Noncash items: | |||
Depreciation and amortization | 3,400 | 3,103 | 2,891 |
Deferred income taxes | (673) | 130 | (8) |
Share-based compensation | 925 | 800 | 679 |
Other, net | (331) | (944) | (52) |
Net change in other operating items, net of effects from acquisitions and changes in AARP balances: | |||
Accounts receivable | (2,523) | (1,000) | (688) |
Other assets | (1,374) | (1,031) | (2,195) |
Medical costs payable | 4,053 | 2,701 | 152 |
Accounts payable and other liabilities | 1,964 | 1,162 | 5,348 |
Unearned revenues | 126 | (310) | 278 |
Cash flows from operating activities | 26,206 | 22,343 | 22,174 |
Investing activities | |||
Purchases of investments | (18,825) | (17,139) | (16,577) |
Sales of investments | 5,907 | 7,045 | 6,489 |
Maturities of investments | 6,081 | 8,251 | 7,252 |
Cash paid for acquisitions, net of cash assumed | (21,458) | (4,821) | (7,139) |
Purchases of property, equipment and capitalized software | (2,802) | (2,454) | (2,051) |
Cash received from dispositions | 3,414 | 15 | 221 |
Other, net | (793) | (1,269) | (727) |
Cash flows used for investing activities | (28,476) | (10,372) | (12,532) |
Financing activities | |||
Common share repurchases | (7,000) | (5,000) | (4,250) |
Cash dividends paid | (5,991) | (5,280) | (4,584) |
Proceeds from common stock issuances | 1,253 | 1,355 | 1,440 |
Repayments of long-term debt | (3,015) | (3,150) | (3,150) |
Proceeds from (repayments of) short-term borrowings, net | 732 | (1,302) | 872 |
Proceeds from issuance of long-term debt | 14,819 | 6,933 | 4,864 |
Customer funds administered | 5,548 | 622 | 1,677 |
Purchases of redeemable noncontrolling interests | (176) | (1,338) | 0 |
Other, net | (1,944) | (295) | (459) |
Cash flows from (used for) financing activities | 4,226 | (7,455) | (3,590) |
Effect of exchange rate changes on cash and cash equivalents | 34 | (62) | (116) |
Increase in cash and cash equivalents | 1,990 | 4,454 | 5,936 |
Cash and cash equivalents, beginning of period | 21,375 | 16,921 | 10,985 |
Cash and cash equivalents, end of period | 23,365 | 21,375 | 16,921 |
Supplemental cash flow disclosures | |||
Cash paid for interest | 1,945 | 1,653 | 1,704 |
Cash paid for income taxes | $ 5,222 | $ 3,966 | $ 4,935 |
Description of Business (Notes)
Description of Business (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Nature of Operations [Text Block] | Description of BusinessUnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve. |
Basis of Presentation, Uses of
Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Basis of Presentation, Use of Estimates and Significant Accounting Policies Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2022 and 2021, accounts receivables related to products and services were $7.1 billion and $5.4 billion, respectively. In 2022 and 2021, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2022 or 2021. For the years ended December 31, 2022, 2021 and 2020, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.5 billion, of which approximately half is expected to be recognized in the next three See Note 14 for disaggregation of revenue by segment and type. Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2022. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes, and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months. Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services. Cash, Cash Equivalents and Investments Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments, with certain exceptions, are measured at fair value with changes in fair value recognized in net earnings. The Company excludes unrealized gains and losses on investments in available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Securities downgraded below policy minimums after purchase will be disposed of in accordance with the Company’s investment policy. Assets Under Management The Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program) and to AARP members and non-members under separate Medicare Advantage and Medicare Part D arrangements. The products and services under the AARP Program include supplemental Medicare benefits, hospital indemnity insurance, including insurance for individuals between 50 to 64 years of age, and other related products. Pursuant to the Company’s agreement with AARP, program assets are managed separately from the Company’s general investment portfolio and are used to pay costs associated with the AARP Program. These assets are invested at the Company’s discretion, within investment guidelines approved by AARP. The Company does not guarantee any rates of return on these investments and, upon any transfer of the AARP Program contract to another entity, the Company would transfer cash equal in amount to the fair value of these investments at the date of transfer to the entity. Because the purpose of these assets is to fund the medical costs payable, the rate stabilization fund (RSF) liabilities and other related liabilities associated with this AARP contract, assets under management are classified as current assets, consistent with the classification of these liabilities. Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2022 and 2021, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $8.2 billion and $7.2 billion, respectively. As of December 31, 2022 and 2021, the Company’s Medicare Part D receivables amounted to $1.3 billion and $3.4 billion, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include pharmaceutical drug and supplies inventory of $3.5 billion and $2.9 billion as of December 31, 2022 and 2021, respectively. Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life. Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2022, 2021 and 2020. Intangible Assets The Company’s intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2022, 2021 and 2020. Other Current Liabilities Other current liabilities include health savings account deposits ($13.5 billion and $11.4 billion as of December 31, 2022 and 2021, respectively), accruals for premium rebates payable, the RSF associated with the AARP Program, the current portion of future policy benefits and customer balances. Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred. Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2022 and 2021: (in millions) 2022 2021 Redeemable noncontrolling interests, beginning of period $ 1,434 $ 2,211 Net earnings 113 87 Acquisitions 3,108 28 Redemptions (176) (1,338) Distributions (82) (255) Fair value and other adjustments 500 701 Redeemable noncontrolling interests, end of period $ 4,897 $ 1,434 Share-Based Compensation The Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four four |
Investments (Notes)
Investments (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Investments [Abstract] | |
Investments [Text Block] | Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000 December 31, 2021 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,206 $ 23 $ (31) $ 3,198 State and municipal obligations 6,829 297 (20) 7,106 Corporate obligations 20,947 372 (145) 21,174 U.S. agency mortgage-backed securities 5,868 88 (55) 5,901 Non-U.S. agency mortgage-backed securities 2,819 42 (23) 2,838 Total debt securities - available-for-sale 39,669 822 (274) 40,217 Debt securities - held-to-maturity: U.S. government and agency obligations 511 2 (2) 511 State and municipal obligations 30 2 — 32 Corporate obligations 100 — — 100 Total debt securities - held-to-maturity 641 4 (2) 643 Total debt securities $ 40,310 $ 826 $ (276) $ 40,860 Nearly all of the Company’s investments in mortgage-backed securities were rated “Triple A” as of December 31, 2022. The Company held $3.7 billion and $3.5 billion of equity securities as of December 31, 2022 and 2021, respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments, venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.5 billion and $1.3 billion of equity method investments in operating businesses in the health care sector, as of December 31, 2022 and 2021, respectively. The allowance for credit losses on held-to-maturity securities as of December 31, 2022 and 2021 was not material. The amortized cost and fair value of debt securities as of December 31, 2022, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,713 $ 4,682 $ 374 $ 369 Due after one year through five years 13,135 12,404 265 256 Due after five years through ten years 12,210 10,897 37 36 Due after ten years 5,412 4,968 20 18 U.S. agency mortgage-backed securities 7,379 6,586 — — Non-U.S. agency mortgage-backed securities 3,077 2,784 — — Total debt securities $ 45,926 $ 42,321 $ 696 $ 679 The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross December 31, 2022 U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664) December 31, 2021 U.S. government and agency obligations $ 1,976 $ (18) $ 249 $ (13) $ 2,225 $ (31) State and municipal obligations 1,386 (19) 31 (1) 1,417 (20) Corporate obligations 9,357 (130) 376 (15) 9,733 (145) U.S. agency mortgage-backed securities 3,078 (52) 116 (3) 3,194 (55) Non-U.S. agency mortgage-backed securities 1,321 (18) 114 (5) 1,435 (23) Total debt securities - available-for-sale $ 17,118 $ (237) $ 886 $ (37) $ 18,004 $ (274) The Company’s unrealized losses from all securities as of December 31, 2022 were generated from approximately 35,000 positions out of a total of 41,000 positions. The Company believes it will collect the timely principal and interest due on its debt securities having an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase. As of December 31, 2022, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities as of December 31, 2022 and 2021 was not material. |
Fair Value (Notes)
Fair Value (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value [Text Block] | Fair ValueCertain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input which is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The fair value hierarchy is summarized as follows: Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets. Level 2 — Other observable inputs, either directly or indirectly, including: • Quoted prices for similar assets/liabilities in active markets; • Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time); • Inputs other than quoted prices observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and • Inputs corroborated by other observable market data. Level 3 — Unobservable inputs cannot be corroborated by observable market data. There were no transfers in or out of Level 3 financial assets or liabilities during the years ended December 31, 2022 or 2021. Nonfinancial assets and liabilities or financial assets and liabilities measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. For the years ended December 31, 2022 and 2021, the Company recognized $211 million and $840 million, respectively, of unrealized gains in investment and other income related to fair value adjustments on equity securities primarily in our venture portfolio, based upon transaction of the same or similar security. There were no other significant fair value adjustments for these assets and liabilities recorded during the years ended December 31, 2022 or 2021. The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below: Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments which do not trade on a regular basis in active markets are classified as Level 2. Debt and Equity Securities. Fair values of debt securities and equity securities reported at fair value on a recurring basis are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs currently observable in the markets for similar securities. Inputs often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment to the prices obtained from the pricing service. Fair values of debt securities which do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2. Fair value estimates for Level 1 and Level 2 equity securities reported at fair value on a recurring basis are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices. The fair values of Level 3 investments in corporate bonds, which are not a significant portion of our investments, are estimated using valuation techniques relying heavily on management assumptions and qualitative observations. Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on such understanding. Assets Under Management. Assets under management consists of debt securities and other investments held to fund costs associated with the AARP Program and are priced and classified using the same methodologies as the Company’s investments in debt and equity securities. Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 % December 31, 2021 Cash and cash equivalents $ 21,359 $ 16 $ — $ 21,375 Debt securities - available-for-sale: U.S. government and agency obligations 3,017 181 — 3,198 State and municipal obligations — 7,106 — 7,106 Corporate obligations 40 20,916 218 21,174 U.S. agency mortgage-backed securities — 5,901 — 5,901 Non-U.S. agency mortgage-backed securities — 2,838 — 2,838 Total debt securities - available-for-sale 3,057 36,942 218 40,217 Equity securities 2,090 23 64 2,177 Assets under management 1,972 2,376 101 4,449 Total assets at fair value $ 28,478 $ 39,357 $ 383 $ 68,218 Percentage of total assets at fair value 42 % 57 % 1 % 100 % The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823 December 31, 2021 Debt securities - held-to-maturity $ 534 $ 102 $ 7 $ 643 $ 641 Long-term debt and other financing obligations $ — $ 52,583 $ — $ 52,583 $ 46,003 |
Property, Plant, and Capitalize
Property, Plant, and Capitalized Software (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment Disclosure [Text Block] | Property, Equipment and Capitalized Software A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2022 December 31, 2021 Land and improvements $ 697 $ 502 Buildings and improvements 5,519 4,882 Computer equipment 2,093 1,851 Furniture and fixtures 2,113 2,014 Less accumulated depreciation (4,499) (3,857) Property and equipment, net 5,923 5,392 Capitalized software 6,636 5,712 Less accumulated amortization (2,431) (2,135) Capitalized software, net 4,205 3,577 Total property, equipment and capitalized software, net $ 10,128 $ 8,969 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill [Line Items] | |
Goodwill Disclosure [Text Block] | Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill, by reportable segment, were as follows: (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Consolidated Balance at January 1, 2021 $ 27,785 $ 19,844 $ 8,173 $ 15,535 $ 71,337 Acquisitions 60 4,648 96 — 4,804 Foreign currency effects and other adjustments, net (456) (268) 350 28 (346) Balance at December 31, 2021 27,389 24,224 8,619 15,563 75,795 Acquisitions 19 5,158 8,623 3,910 17,710 Foreign currency effects and other adjustments, net (13) (144) 2 2 (153) Balance at December 31, 2022 $ 27,395 $ 29,238 $ 17,244 $ 19,475 $ 93,352 The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows: December 31, 2022 December 31, 2021 (in millions) Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Customer-related $ 16,303 $ (5,179) $ 11,124 $ 13,011 $ (4,697) $ 8,314 Trademarks and technology 2,398 (704) 1,694 1,630 (739) 891 Trademarks and other indefinite-lived 661 — 661 617 — 617 Other 1,176 (254) 922 422 (200) 222 Total $ 20,538 $ (6,137) $ 14,401 $ 15,680 $ (5,636) $ 10,044 The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations consisted of the following by year of acquisition: 2022 2021 (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 3,927 15 years $ 484 9 years Trademarks and technology 1,058 6 years 147 5 years Other 776 13 years 29 11 years Total acquired finite-lived intangible assets $ 5,761 13 years $ 660 8 years Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows: (in millions) 2023 $ 1,562 2024 1,478 2025 1,360 2026 1,206 2027 1,154 |
Medical Costs Payable (Notes)
Medical Costs Payable (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Insurance [Abstract] | |
Medical Costs Payable | Medical Costs Payable The following table shows the components of the change in medical costs payable for the years ended December 31: (in millions) 2022 2021 2020 Medical costs payable, beginning of period $ 24,483 $ 21,872 $ 21,690 Acquisitions 308 88 316 Reported medical costs: Current year 211,252 188,631 160,276 Prior years (410) (1,720) (880) Total reported medical costs 210,842 186,911 159,396 Medical payments: Payments for current year (184,049) (165,524) (139,974) Payments for prior years (22,528) (18,864) (19,556) Total medical payments (206,577) (184,388) (159,530) Medical costs payable, end of period $ 29,056 $ 24,483 $ 21,872 For the year ended December 31, 2022, prior year’s medical cost reserve development included no individual factors that were significant. For the years ended December 31, 2021 and 2020, prior years’ medical cost reserve development was primarily driven by lower than expected care activity. Additionally, prior years’ medical cost reserve development in the year ended December 31, 2021 was driven by care patterns disrupted by COVID-19. Medical costs payable included IBNR of $20.0 billion and $17.1 billion at December 31, 2022 and 2021, respectively. Substantially all of the IBNR balance as of December 31, 2022 relates to the current year. The following is information about incurred and paid medical cost development as of December 31, 2022: Net Incurred Medical Costs (in millions) For the Years Ended December 31, Year 2021 2022 2021 $ 188,631 $ 188,407 2022 211,252 Total $ 399,659 Net Cumulative Medical Payments (in millions) For the Years Ended December 31, Year 2021 2022 2021 $ (165,524) $ (186,944) 2022 (184,049) Total (370,993) Net remaining outstanding liabilities prior to 2021 390 Total medical costs payable $ 29,056 |
Short-Term Borrowings and Long-
Short-Term Borrowings and Long-Term Debt (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
Short-Term Borrowings and Long-Term Debt [Text Block] | Short-Term Borrowings and Long-Term Debt Short-term borrowings and senior unsecured long-term debt consisted of the following: Carrying Value As of December 31, (in millions, except percentages) 2022 2021 Commercial paper $ 800 $ — $1,100 million 2.875% notes due March 2022 — 1,097 $1,000 million 3.350% notes due July 2022 — 999 $900 million 2.375% notes due October 2022 — 899 $15 million 0.000% notes due November 2022 — 14 $625 million 2.750% notes due February 2023 622 632 $750 million 2.875% notes due March 2023 746 768 $750 million 3.500% notes due June 2023 750 749 $750 million 3.500% notes due February 2024 749 748 $1,000 million 0.550% notes due May 2024 998 996 $750 million 2.375% notes due August 2024 749 748 $500 million 5.000% notes due October 2024 499 — $2,000 million 3.750% notes due July 2025 1,995 1,994 $750 million 5.150% notes due October 2025 747 — $300 million 3.700% notes due December 2025 299 299 $500 million 1.250% notes due January 2026 498 497 $1,000 million 3.100% notes due March 2026 998 997 $1,000 million 1.150% notes due May 2026 893 972 $750 million 3.450% notes due January 2027 748 747 $625 million 3.375% notes due April 2027 622 621 $600 million 3.700% notes due May 2027 597 — $950 million 2.950% notes due October 2027 943 942 $1,000 million 5.250% notes due February 2028 1,008 — $1,150 million 3.850% notes due June 2028 1,145 1,144 $850 million 3.875% notes due December 2028 845 844 $900 million 4.000% notes due May 2029 849 — $1,000 million 2.875% notes due August 2029 886 1,023 $1,250 million 5.300% notes due February 2030 1,269 — $1,250 million 2.000% notes due May 2030 1,237 1,235 $1,500 million 2.300% notes due May 2031 1,256 1,482 $1,500 million 4.200% notes due May 2032 1,393 — $2,000 million 5.350% notes due February 2033 2,037 — $1,000 million 4.625% notes due July 2035 993 993 $850 million 5.800% notes due March 2036 840 839 $500 million 6.500% notes due June 2037 493 492 $650 million 6.625% notes due November 2037 642 642 $1,100 million 6.875% notes due February 2038 1,079 1,078 $1,250 million 3.500% notes due August 2039 1,242 1,242 $1,000 million 2.750% notes due May 2040 967 966 $300 million 5.700% notes due October 2040 296 296 $350 million 5.950% notes due February 2041 346 346 $1,500 million 3.050% notes due May 2041 1,483 1,483 Carrying Value As of December 31, (in millions, except percentages) 2022 2021 $600 million 4.625% notes due November 2041 590 589 $502 million 4.375% notes due March 2042 486 485 $625 million 3.950% notes due October 2042 609 608 $750 million 4.250% notes due March 2043 736 736 $2,000 million 4.750% notes due July 2045 1,975 1,974 $750 million 4.200% notes due January 2047 739 739 $725 million 4.250% notes due April 2047 718 718 $950 million 3.750% notes due October 2047 935 934 $1,350 million 4.250% notes due June 2048 1,331 1,330 $1,100 million 4.450% notes due December 2048 1,087 1,087 $1,250 million 3.700% notes due August 2049 1,236 1,236 $1,250 million 2.900% notes due May 2050 1,210 1,209 $2,000 million 3.250% notes due May 2051 1,971 1,970 $2,000 million 4.750% notes due May 2052 1,965 — $2,000 million 5.875% notes due February 2053 1,968 — $1,250 million 3.875% notes due August 2059 1,228 1,228 $1,000 million 3.125% notes due May 2060 966 965 $1,000 million 4.950% notes due May 2062 981 — $1,500 million 6.050% notes due February 2063 1,466 — Total short-term borrowings and long-term debt $ 56,756 $ 44,632 The Company’s long-term debt obligations also included $0.9 billion and $1.4 billion of other financing obligations, of which $192 million and $611 million were current as of December 31, 2022 and 2021, respectively. Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2023 $ 3,117 2024 3,136 2025 3,186 2026 2,636 2027 3,061 Thereafter 43,638 Short-Term Borrowings Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. The Company has $6.0 billion five three Debt Covenants The Company’s bank credit facilities contain various covenants, including requiring the Company to maintain a debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in compliance with its debt covenants as of December 31, 2022. |
Income Taxes (Notes)
Income Taxes (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Examination [Line Items] | |
Income Tax Disclosure [Text Block] | Income Taxes The current income tax provision reflects the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported. The deferred income tax provision or benefit generally reflects the net change in deferred income tax assets and liabilities during the year, excluding any deferred income tax assets and liabilities of acquired businesses. The components of the provision for income taxes for the years ended December 31 are as follows: (in millions) 2022 2021 2020 Current Provision: Federal $ 4,842 $ 3,451 $ 4,098 State and local 855 481 392 Foreign 680 516 491 Total current provision 6,377 4,448 4,981 Deferred (benefit) provision (673) 130 (8) Total provision for income taxes $ 5,704 $ 4,578 $ 4,973 The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows: (in millions, except percentages) 2022 2021 2020 Tax provision at the U.S. federal statutory rate $ 5,532 21.0 % $ 4,685 21.0 % $ 4,356 21.0 % State income taxes, net of federal benefit 621 2.4 419 1.9 315 1.5 Share-based awards - excess tax benefit (110) (0.4) (100) (0.4) (130) (0.6) Non-deductible compensation 150 0.6 144 0.6 134 0.7 Health insurance tax — — — — 626 3.0 Foreign rate differential (265) (1.0) (246) (1.1) (164) (0.8) Other, net (224) (0.9) (324) (1.5) (164) (0.8) Provision for income taxes $ 5,704 21.7 % $ 4,578 20.5 % $ 4,973 24.0 % Deferred income tax assets and liabilities are recognized for the differences between the financial and income tax reporting bases of assets and liabilities based on enacted tax rates and laws. The components of deferred income tax assets and liabilities as of December 31 are as follows: (in millions) 2022 2021 Deferred income tax assets: Accrued expenses and allowances $ 707 $ 723 U.S. federal and state net operating loss carryforwards 540 287 Share-based compensation 154 117 Nondeductible liabilities 341 296 Non-U.S. tax loss carryforwards 631 435 Lease liability 972 1,284 Net unrealized losses on investments 829 — Other-domestic 291 228 Other-non-U.S. 423 376 Subtotal 4,888 3,746 Less: valuation allowances (291) (198) Total deferred income tax assets 4,597 3,548 Deferred income tax liabilities: U.S. federal and state intangible assets (3,520) (2,658) Non-U.S. goodwill and intangible assets (550) (512) Capitalized software (548) (833) Depreciation and amortization (520) (349) Prepaid expenses (275) (256) Outside basis in partnerships (653) (565) Lease right-of-use asset (958) (1,267) Net unrealized gains on investments — (125) Other-non-U.S. (342) (248) Total deferred income tax liabilities (7,366) (6,813) Net deferred income tax liabilities $ (2,769) $ (3,265) Valuation allowances are provided when it is considered more likely than not deferred tax assets will not be realized. The valuation allowances primarily relate to future tax benefits on certain federal, state and non-U.S. net operating loss carryforwards. Gross federal net operating loss carryforwards of $490 million expire beginning in 2023 through 2037 and $611 million have an indefinite carryforward period; state net operating loss carryforwards expire beginning in 2023 through 2042, with some having an indefinite carryforward period. Substantially all of the non-U.S. tax loss carryforwards have indefinite carryforward periods. As of December 31, 2022, the Company’s undistributed earnings from non-U.S. subsidiaries are intended to be indefinitely reinvested in non-U.S. operations, and therefore no U.S. deferred taxes have been recorded. Taxes payable on the remittance of such earnings would be minimal. A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows: (in millions) 2022 2021 2020 Gross unrecognized tax benefits, beginning of period $ 2,310 $ 1,829 $ 1,423 Gross increases: Current year tax positions 586 538 416 Prior year tax positions 206 10 120 Gross decreases: Prior year tax positions (21) (47) (130) Statute of limitations lapses — (20) — Gross unrecognized tax benefits, end of period $ 3,081 $ 2,310 $ 1,829 The Company believes it is reasonably possible its liability for unrecognized tax benefits will decrease in the next twelve months by $260 million as a result of audit settlements and the expiration of statutes of limitations. The Company classifies net interest and penalties associated with uncertain income tax positions as income taxes within its Consolidated Statements of Operations. During the years ended December 31, 2022, 2021 and 2020, the Company recognized $64 million, $66 million and $52 million of net interest and penalties, respectively. The Company had $253 million and $194 million of accrued interest and penalties for uncertain tax positions as of December 31, 2022 and 2021, respectively. These amounts are not included in the reconciliation above. As of December 31, 2022, there were $1.7 billion of unrecognized tax benefits which, if recognized, would affect the effective tax rate. The Company currently files income tax returns in the United States, various states and localities and non-U.S. jurisdictions. The U.S. Internal Revenue Service (IRS) has completed exams on the consolidated income tax returns for fiscal years 2016 and prior. The Company’s 2017 through 2020 tax years are under review by the IRS under its Compliance Assurance Program. With the exception of a few states, the Company is no longer subject to income tax examinations prior to the 2014 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward. |
Shareholders' Equity (Notes)
Shareholders' Equity (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Shareholders' Equity [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | Shareholders' Equity Regulatory Capital and Dividend Restrictions The Company’s regulated insurance and HMO subsidiaries are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions which may be paid to their parent companies. In the United States, most of these state regulations and standards are generally consistent with model regulations established by the NAIC. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary’s level of statutory net income and statutory capital and surplus. These dividends are referred to as “ordinary dividends” and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an “extraordinary dividend” and must receive prior regulatory approval. For the year ended December 31, 2022, the Company’s domestic insurance and HMO subsidiaries paid their parent companies dividends of $8.8 billion, including $7.4 billion of extraordinary dividends. For the year ended December 31, 2021, the Company’s domestic insurance and HMO subsidiaries paid their parent companies dividends of $8.0 billion, including $4.7 billion of extraordinary dividends. The Company's global financially regulated subsidiaries had estimated aggregate statutory capital and surplus of $33.8 billion as of December 31, 2022. The estimated statutory capital and surplus necessary to satisfy regulatory requirements of the Company's global financially regulated subsidiaries was approximately $15.4 billion as of December 31, 2022. Optum Bank must meet minimum capital requirements of the FDIC under the capital adequacy rules to which it is subject. At December 31, 2022, the Company believes Optum Bank met the FDIC requirements to be considered “Well Capitalized.” Share Repurchase Program Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured share repurchase programs), subject to certain restrictions. In June 2018, the Board of Directors renewed the Company’s share repurchase program with an authorization to repurchase up to 100 million shares of its common stock. A summary of common share repurchases for the years ended December 31, 2022 and 2021 is as follows: Years Ended December 31, (in millions, except per share data) 2022 2021 Common share repurchases, shares 14 13 Common share repurchases, average price per share $ 501.67 $ 389.92 Common share repurchases, aggregate cost $ 7,000 $ 5,000 Board authorized shares remaining 31 45 Dividends In June 2022, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $6.60 compared to $5.80 per share, which the Company had paid since June 2021. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change. The following table provides details of the Company’s 2022 dividend payments: Payment Date Amount per Share Total Amount Paid (in millions) March 22 $ 1.45 $ 1,363 June 28 1.65 1,545 September 20 1.65 1,542 December 13 1.65 1,541 |
Share-Based Compensation (Notes
Share-Based Compensation (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based Payment Arrangement [Text Block] | Share-Based Compensation The Company’s outstanding share-based awards consist mainly of non-qualified stock options and restricted shares. As of December 31, 2022, the Company had 59 million shares available for future grants of share-based awards under the 2020 Stock Incentive Plan. As of December 31, 2022, there were 18 million shares of common stock available for issuance under the ESPP. Stock Options Stock option activity for the year ended December 31, 2022 is summarized in the table below: Shares Weighted- Weighted- Aggregate (in millions) (in years) (in millions) Outstanding at beginning of period 25 $ 241 Granted 4 459 Exercised (5) 215 Forfeited (1) 356 Outstanding at end of period 23 281 5.8 $ 5,914 Exercisable at end of period 13 213 4.4 4,170 Vested and expected to vest, end of period 23 278 5.7 5,854 Restricted Shares Restricted share activity for the year ended December 31, 2022 is summarized in the table below: (shares in millions) Shares Weighted-Average Nonvested at beginning of period 4 $ 303 Granted 2 483 Vested (2) 287 Nonvested at end of period 4 401 Other Share-Based Compensation Data (in millions, except per share amounts) For the Years Ended December 31, 2022 2021 2020 Stock Options Weighted-average grant date fair value of shares granted, per share $ 116 $ 71 $ 54 Total intrinsic value of stock options exercised 1,419 1,519 1,736 Restricted Shares Weighted-average grant date fair value of shares granted, per share 483 352 303 Total fair value of restricted shares vested $ 760 $ 560 $ 574 Employee Stock Purchase Plan Number of shares purchased 1 1 1 Share-Based Compensation Items Share-based compensation expense, before tax $ 925 $ 800 $ 679 Share-based compensation expense, net of tax effects 836 719 619 Income tax benefit realized from share-based award exercises 207 173 208 (in millions, except years) December 31, 2022 Unrecognized compensation expense related to share awards $ 1,165 Weighted-average years to recognize compensation expense 1.3 Share-Based Compensation Recognition and Estimates The principal assumptions the Company used in calculating grant-date fair value for stock options were as follows: For the Years Ended December 31, 2022 2021 2020 Risk-free interest rate 1.9% - 4.3% 0.7% - 1.2% 0.2% - 1.4% Expected volatility 30.6% -30.8% 29.2% - 29.8% 22.2% - 29.5% Expected dividend yield 1.2% 1.3% - 1.5% 1.4% - 1.7% Forfeiture rate 5.0% 5.0% 5.0% Expected life in years 4.7 4.8 5.1 Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company’s common stock and the implied volatility from exchange-traded options on the Company’s common stock. Expected dividend yields are based on the per share cash dividend paid by the Company. The Company uses historical data to estimate option exercises and forfeitures within the valuation model. The expected lives of options granted represents the period of time the awards granted are expected to be outstanding based on historical exercise patterns. Other Employee Benefit Plans The Company offers a 401(k) plan for its employees. Compensation expense related to this plan was not material for 2022, 2021 and 2020. In addition, the Company maintains non-qualified, deferred compensation plans, which allow certain members of senior management and executives to defer portions of their salary or bonus. The deferrals are recorded within long-term investments with an approximately equal amount in other liabilities in the Consolidated Balance Sheets. The total deferrals are distributable based upon termination of employment or other periods, as elected under each plan and were $1.6 billion and $1.8 billion as of December 31, 2022 and 2021, respectively. |
Commitments and Contingencies (
Commitments and Contingencies (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Commitments and Contingencies Leases Operating lease costs, including immaterial variable and short-term lease costs, were $1.3 billion, $1.2 billion and $1.1 billion for the years ended December 31, 2022, 2021 and 2020, respectively. Cash payments made on the Company’s operating lease liabilities were $996 million, $921 million and $865 million for the years ended December 31, 2022, 2021 and 2020, respectively, which were classified within operating activities in the Consolidated Statements of Cash Flows. As of December 31, 2022, the Company’s weighted-average remaining lease term and weighted-average discount rate for its operating leases were 8.6 years and 3.4%, respectively. As of December 31, 2022, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Minimum Lease Payments 2023 $ 997 2024 858 2025 702 2026 578 2027 475 Thereafter 2,028 Total future minimum lease payments 5,638 Less imputed interest (808) Total $ 4,830 Other Commitments The Company provides guarantees related to its service level under certain contracts. If minimum standards are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2022, 2021 or 2020. Pending Acquisitions As of December 31, 2022, the Company has entered into agreements to acquire companies in the health care sector, most notably, LHC Group, Inc. (NASDAQ: LHCG), subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $9 billion. The Company completed the acquisition of LHC Group, Inc. on February 22, 2023. Legal Matters The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the IRS, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the FDIC, Consumer Financial Protection Bureau, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status. |
Business Combinations (Notes)
Business Combinations (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Business Combination Disclosure [Text Block] | Business Combinations On October 3, 2022, the Company acquired all of the outstanding common shares of Change Healthcare Inc. (Change) and funded Change’s payoff of its outstanding debt and credit facility for a total of $13.9 billion in cash. The combination of the Company and Change will connect and simplify the core clinical, administrative and payment processes health care providers and payers depend on to serve patients. Change brings key technologies, connections and advanced clinical decision, administrative and financial support capabilities, enabling better workflow and transactional connectivity across the health care system. Subsequent to closing and as planned, the Company sold Change’s claims editing business to an affiliate of investment funds of TPG Inc. for $2.2 billion in cash. The net assets and net liabilities associated with this sale were classified as held-for-sale at the time of acquisition. There was no gain or loss associated with this transaction. During the year ended December 31, 2022, the Company completed several other business combinations for total consideration of $8.8 billion. The Company also sold other businesses for $1.2 billion of cash, with a carrying value of $600 million, and the difference reflected in the Consolidated Statement of Operations. Acquired assets (liabilities) at acquisition date were: (in millions) Change Other Acquisitions Total Cash and cash equivalents $ 222 $ 523 $ 745 Accounts receivable and other current assets 925 696 1,621 Assets held-for-sale 2,310 — 2,310 Property, equipment and other long-term assets 254 1,882 2,136 Other intangible assets 4,050 1,764 5,814 Total identifiable assets acquired 7,761 4,865 12,626 Medical costs payable — (308) (308) Accounts payable and other current liabilities (1,017) (843) (1,860) Liabilities held-for-sale (101) — (101) Other long-term liabilities (1,193) (713) (1,906) Total identifiable liabilities acquired (2,311) (1,864) (4,175) Total net identifiable assets 5,450 3,001 8,451 Goodwill 8,496 9,214 17,710 Redeemable noncontrolling interests — (3,108) (3,108) Nonredeemable noncontrolling interests — (370) (370) Net assets acquired $ 13,946 $ 8,737 $ 22,683 The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent liabilities, are finalized. The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired consisted of the following: Change Other Acquisitions Total (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 3,063 15 years $ 864 13 years $ 3,927 15 years Trademarks and technology 977 6 years 81 4 years 1,058 6 years Other 10 1 year 766 13 years 776 13 years Total acquired finite-lived intangible assets $ 4,050 13 years $ 1,711 13 years $ 5,761 13 years The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through December 31, 2022, acquired entities impact on revenues and net earnings was not material. Unaudited pro forma revenues and net earnings for the years ended December 31, 2022 and 2021, as if the business combinations had occurred on January 1, 2021, were immaterial for both periods. |
Segment Financial Information (
Segment Financial Information (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Text Block] | Segment Financial Information Factors used to determine the Company’s reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company’s chief operating decision maker to evaluate its results of operations. Reportable segments with similar economic characteristics, products and services, customers, distribution methods and operational processes which operate in a similar regulatory environment are combined. The following is a description of the types of products and services from which each of the Company’s four reportable segments derives its revenues: • UnitedHealthcare includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. The U.S. businesses share significant common assets, including a contracted network of physicians, health care professionals, hospitals and other facilities, information technology and consumer engagement infrastructure and other resources. Domestically, UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services for employers and individuals. Globally, UnitedHealthcare Employer & Individual provides health and dental benefits and hospital and clinical services to employers and individuals in South America and other diversified global businesses. UnitedHealthcare Medicare & Retirement provides health care coverage and health and well-being services to individuals age 50 and older, addressing their unique needs. UnitedHealthcare Community & State provides diversified health care benefits products and services to state programs caring for the economically disadvantaged, the medically underserved and those without the benefit of employer-funded health care coverage. • Optum Health focuses on care delivery, care management, wellness and consumer engagement, and health financial services. Optum Health is building a comprehensive, connected health care delivery and engagement platform by directly providing high-quality care, helping people manage chronic and complex health needs, and proactively engaging consumers in managing their health through in-person, in-home, virtual and digital clinical platforms. • Optum Insight brings together advanced analytics, technology and health care expertise to deliver integrated services and solutions. Hospital systems, physicians, health plans, governments, life sciences companies and other organizations depend on Optum Insight to help them improve performance, achieve efficiency, reduce costs, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system. • Optum Rx offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease/drug therapy management. Optum Rx integrates pharmacy and medical care and is positioned to serve patients with complex clinical needs and consumers looking for a better digital pharmacy experience with transparent pricing. The Company’s accounting policies for reportable segment operations are consistent with those described in the Summary of Significant Accounting Policies (see Note 2 ). Transactions between reportable segments principally consist of sales of pharmacy care products and services to UnitedHealthcare customers by Optum Rx; care delivery, care management services and certain product offerings sold to UnitedHealthcare by Optum Health; and health information and technology solutions, consulting and other services sold to UnitedHealthcare by Optum Insight. These transactions are recorded at management’s estimate of fair value. Transactions with affiliated customers are eliminated in consolidation. Assets and liabilities jointly used are assigned to each reportable segment using estimates of pro-rata usage. Cash and investments are assigned so each reportable segment has working capital and/or at least minimum specified levels of regulatory capital. As a percentage of the Company’s total consolidated revenues, premium revenues from CMS were 38%, 36% and 36% for 2022, 2021 and 2020, respectively, most of which were generated by UnitedHealthcare Medicare & Retirement and included in the UnitedHealthcare segment. U.S. customer revenue represented approximately 97% of consolidated total revenues for 2022, 2021 and 2020. Long-lived fixed assets located in the United States represented approximately 81% and 78% of the total long-lived fixed assets as of December 31, 2022 and 2021, respectively. The non-U.S. revenues and fixed assets are primarily related to UnitedHealthcare Employer & Individual’s international businesses. The following table presents the reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated 2022 Revenues - unaffiliated customers: Premiums $ 238,783 $ 18,374 $ — $ — $ — $ 18,374 $ — $ 257,157 Products — 72 180 37,172 — 37,424 — 37,424 Services 10,035 10,917 4,996 1,603 — 17,516 — 27,551 Total revenues - unaffiliated customers 248,818 29,363 5,176 38,775 — 73,314 — 322,132 Total revenues - affiliated customers — 40,883 9,288 60,936 (2,760) 108,347 (108,347) — Investment and other income 923 928 117 62 — 1,107 — 2,030 Total revenues $ 249,741 $ 71,174 $ 14,581 $ 99,773 $ (2,760) $ 182,768 $ (108,347) $ 324,162 Earnings from operations $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ — $ 28,435 Interest expense — — — — — — (2,092) (2,092) Earnings before income taxes $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ (2,092) $ 26,343 Total assets $ 107,094 $ 68,950 $ 31,090 $ 47,476 $ — $ 147,516 $ (8,905) $ 245,705 Purchases of property, equipment and capitalized software 799 997 698 308 — 2,003 — 2,802 Depreciation and amortization 973 943 841 643 — 2,427 — 3,400 2021 Revenues - unaffiliated customers: Premiums $ 212,381 $ 13,852 $ — $ — $ — $ 13,852 $ — $ 226,233 Products — 32 159 34,246 — 34,437 — 34,437 Services 9,661 9,894 3,936 1,112 — 14,942 — 24,603 Total revenues - unaffiliated customers 222,042 23,778 4,095 35,358 — 63,231 — 285,273 Total revenues - affiliated customers — 29,234 7,867 55,779 (2,013) 90,867 (90,867) — Investment and other income 857 1,053 237 177 — 1,467 — 2,324 Total revenues $ 222,899 $ 54,065 $ 12,199 $ 91,314 $ (2,013) $ 155,565 $ (90,867) $ 287,597 Earnings from operations $ 11,975 $ 4,462 $ 3,398 $ 4,135 $ — $ 11,995 $ — $ 23,970 Interest expense — — — — — — (1,660) (1,660) Earnings before income taxes $ 11,975 $ 4,462 $ 3,398 $ 4,135 $ — $ 11,995 $ (1,660) $ 22,310 Total assets $ 102,967 $ 60,474 $ 16,868 $ 40,181 $ — $ 117,523 $ (8,284) $ 212,206 Purchases of property, equipment and capitalized software 795 791 567 301 — 1,659 — 2,454 Depreciation and amortization 1,004 818 684 597 — 2,099 — 3,103 2020 Revenues - unaffiliated customers: Premiums $ 191,679 $ 9,799 $ — $ — $ — $ 9,799 $ — $ 201,478 Products — 33 135 33,977 — 34,145 — 34,145 Services 8,464 6,815 3,687 1,050 — 11,552 — 20,016 Total revenues - unaffiliated customers 200,143 16,647 3,822 35,027 — 55,496 — 255,639 Total revenues - affiliated customers — 22,481 6,941 52,420 (1,800) 80,042 (80,042) — Investment and other income 732 680 39 51 — 770 — 1,502 Total revenues $ 200,875 $ 39,808 $ 10,802 $ 87,498 $ (1,800) $ 136,308 $ (80,042) $ 257,141 Earnings from operations $ 12,359 $ 3,434 $ 2,725 $ 3,887 $ — $ 10,046 $ — $ 22,405 Interest expense — — — — — — (1,663) (1,663) Earnings before income taxes $ 12,359 $ 3,434 $ 2,725 $ 3,887 $ — $ 10,046 $ (1,663) $ 20,742 Total assets $ 98,229 $ 52,073 $ 15,425 $ 39,280 $ — $ 106,778 $ (7,718) $ 197,289 Purchases of property, equipment and capitalized software 687 715 461 188 — 1,364 — 2,051 Depreciation and amortization 920 703 670 598 — 1,971 — 2,891 |
Schedule I (Notes)
Schedule I (Notes) | 12 Months Ended |
Dec. 31, 2022 | |
Condensed Statement of Income Captions [Line Items] | |
Condensed Financial Information of Parent Company Only Disclosure [Text Block] | Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Balance Sheets (in millions, except per share data) December 31, December 31, Assets Current assets: Cash and cash equivalents $ 266 $ 2,167 Other current assets 753 503 Total current assets 1,019 2,670 Equity in net assets of subsidiaries 136,562 116,907 Long-term notes receivable from subsidiaries 6,201 5,680 Other assets 504 32 Total assets $ 144,286 $ 125,289 Liabilities and shareholders’ equity Current liabilities: Accounts payable and accrued liabilities $ 835 $ 605 Current portion of notes payable to subsidiaries 8,699 8,105 Short-term borrowings and current maturities of long-term debt 2,918 3,009 Total current liabilities 12,452 11,719 Long-term debt, less current maturities 53,838 41,623 Other liabilities 224 187 Total liabilities 66,514 53,529 Commitments and contingencies (Note 4) Shareholders’ equity: Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding — — Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding 9 10 Retained earnings 86,156 77,134 Accumulated other comprehensive loss (8,393) (5,384) Total UnitedHealth Group shareholders’ equity 77,772 71,760 Total liabilities and shareholders’ equity $ 144,286 $ 125,289 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Comprehensive Income For the Years Ended December 31, (in millions) 2022 2021 2020 Revenues: Investment and other income $ 255 $ 494 $ 194 Total revenues 255 494 194 Operating costs: Operating costs 121 40 27 Interest expense 2,110 1,583 1,594 Total operating costs 2,231 1,623 1,621 Loss before income taxes (1,976) (1,129) (1,427) Benefit for income taxes 429 231 300 Loss of parent company (1,547) (898) (1,127) Equity in undistributed income of subsidiaries 21,667 18,183 16,530 Net earnings 20,120 17,285 15,403 Other comprehensive loss (3,009) (1,570) (236) Comprehensive income $ 17,111 $ 15,715 $ 15,167 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Cash Flows For the Years Ended December 31, (in millions) 2022 2021 2020 Operating activities Cash flows from operating activities $ 14,754 $ 11,439 $ 8,842 Investing activities Issuances of notes to subsidiaries (567) (444) (628) Repayments of notes to subsidiaries 281 37 1,089 Cash paid for acquisitions (20,728) (4,953) (7,706) Return of capital to parent company 1,424 245 943 Capital contributions to subsidiaries (570) (747) (43) Cash received from dispositions 2,787 — 143 Cash flows used for investing activities (17,373) (5,862) (6,202) Financing activities Common stock repurchases (7,000) (5,000) (4,250) Proceeds from common stock issuances 1,253 1,355 1,440 Cash dividends paid (5,991) (5,280) (4,584) Proceed from (repayments of) short-term borrowings, net 732 (1,302) 872 Proceeds from issuance of long-term debt 14,819 6,933 4,864 Repayments of long-term debt (3,015) (3,150) (3,150) Proceeds from notes from subsidiaries 594 3,223 2,818 Other, net (674) (447) (438) Cash flows from (used for) financing activities 718 (3,668) (2,428) (Decrease) increase in cash and cash equivalents (1,901) 1,909 212 Cash and cash equivalents, beginning of period 2,167 258 46 Cash and cash equivalents, end of period $ 266 $ 2,167 $ 258 Supplemental cash flow disclosures Cash paid for interest $ 1,969 $ 1,575 $ 1,633 Cash paid for income taxes 4,298 3,050 4,185 See Notes to the Condensed Financial Statements of Registrant Schedule I Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Notes to Condensed Financial Statements 1. Basis of Presentation UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” 2. Subsidiary Transactions Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries. Dividends and Capital Distributions. Cash dividends received from subsidiaries and included in Cash Flows from Operating Activities in the Condensed Statements of Cash Flows were $15.6 billion, $10.8 billion and $10.0 billion in 2022, 2021 and 2020, respectively. Additionally, $1.4 billion, $0.2 billion and $0.9 billion in cash were received as a return of capital to the parent company during 2022, 2021 and 2020, respectively. Discussion of short-term borrowings and long-term debt can be found in Note 8 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” Long-term debt obligations of the parent company do not include other financing obligations at subsidiaries which totaled $0.9 billion and $1.4 billion at December 31, 2022 and 2021. Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2023 $ 2,925 2024 3,000 2025 3,050 2026 2,500 2027 2,925 Thereafter 43,502 UnitedHealth Group’s parent company had notes payable to subsidiaries of $8.7 billion and $8.1 billion as of December 31, 2022 and 2021, respectively, which included on-demand features. 4. Commitments and Contingencies Certain regulated subsidiaries are guaranteed by UnitedHealth Group’s parent company in the event of insolvency. UnitedHealth Group’s parent company also provides guarantees related to its service level under certain contracts. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2022, 2021 or 2020. For a summary of commitments and contingencies, see Note 12 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data . ” |
Basis of Presentation, Uses o_2
Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. |
Revenue [Policy Text Block] | Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2022 and 2021, accounts receivables related to products and services were $7.1 billion and $5.4 billion, respectively. In 2022 and 2021, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2022 or 2021. For the years ended December 31, 2022, 2021 and 2020, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.5 billion, of which approximately half is expected to be recognized in the next three See Note 14 for disaggregation of revenue by segment and type. |
Medical Costs and Medical Costs Payable [Policy Text Block] | Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2022. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes, and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months. |
Cost of Goods and Service [Policy Text Block] | Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash, Cash Equivalents and Investments Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. |
Investment, Policy [Policy Text Block] | Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments, with certain exceptions, are measured at fair value with changes in fair value recognized in net earnings. The Company excludes unrealized gains and losses on investments in available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. |
AARP Assets Under Management [Policy Text Block] | Assets Under Management The Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program) and to AARP members and non-members under separate Medicare Advantage and Medicare Part D arrangements. The products and services under the AARP Program include supplemental Medicare benefits, hospital indemnity insurance, including insurance for individuals between 50 to 64 years of age, and other related products. Pursuant to the Company’s agreement with AARP, program assets are managed separately from the Company’s general investment portfolio and are used to pay costs associated with the AARP Program. These assets are invested at the Company’s discretion, within investment guidelines approved by AARP. The Company does not guarantee any rates of return on these investments and, upon any transfer of the AARP Program contract to another entity, the Company would transfer cash equal in amount to the fair value of these investments at the date of transfer to the entity. Because the purpose of these assets is to fund the medical costs payable, the rate stabilization fund (RSF) liabilities and other related liabilities associated with this AARP contract, assets under management are classified as current assets, consistent with the classification of these liabilities. |
Receivable [Policy Text Block] | Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2022 and 2021, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $8.2 billion and $7.2 billion, respectively. As of December 31, 2022 and 2021, the Company’s Medicare Part D receivables amounted to $1.3 billion and $3.4 billion, respectively. |
Prepaid and Other Current Assets Policy | Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include pharmaceutical drug and supplies inventory of $3.5 billion and $2.9 billion as of December 31, 2022 and 2021, respectively. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life. |
Lessee, Leases [Policy Text Block] | Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet |
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] | Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2022, 2021 and 2020. |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible Assets The Company’s intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2022, 2021 and 2020. |
Other Current Liabilities [Policy Text Block] | Other Current Liabilities Other current liabilities include health savings account deposits ($13.5 billion and $11.4 billion as of December 31, 2022 and 2021, respectively), accruals for premium rebates payable, the RSF associated with the AARP Program, the current portion of future policy benefits and customer balances. |
Deferred Policy Acquisition Costs, Policy [Policy Text Block] | Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred. |
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] | Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2022 and 2021: (in millions) 2022 2021 Redeemable noncontrolling interests, beginning of period $ 1,434 $ 2,211 Net earnings 113 87 Acquisitions 3,108 28 Redemptions (176) (1,338) Distributions (82) (255) Fair value and other adjustments 500 701 Redeemable noncontrolling interests, end of period $ 4,897 $ 1,434 |
Share-based Payment Arrangement [Policy Text Block] | Share-Based CompensationThe Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four four |
Earnings Per Share, Policy [Policy Text Block] | Net Earnings Per Common Share The Company computes basic earnings per common share attributable to UnitedHealth Group common shareholders by dividing net earnings attributable to UnitedHealth Group common shareholders by the weighted-average number of common shares outstanding during the period. The Company determines diluted net earnings per common share attributable to UnitedHealth Group common shareholders using the weighted-average number of common shares outstanding during the period, adjusted for potentially dilutive shares associated with stock options, restricted shares and the ESPP (collectively, common stock equivalents), using the treasury stock method. The treasury stock method assumes a hypothetical issuance of shares to settle the share-based awards, with the assumed proceeds used to purchase common stock at the average market price for the period. Assumed proceeds include the amount the employee must pay upon exercise and the average unrecognized compensation cost. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares. |
Fair Value Fair Value (Policies
Fair Value Fair Value (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value Measurement, Policy [Policy Text Block] | Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input which is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The fair value hierarchy is summarized as follows: Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets. Level 2 — Other observable inputs, either directly or indirectly, including: • Quoted prices for similar assets/liabilities in active markets; • Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time); • Inputs other than quoted prices observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and • Inputs corroborated by other observable market data. Level 3 — Unobservable inputs cannot be corroborated by observable market data. There were no transfers in or out of Level 3 financial assets or liabilities during the years ended December 31, 2022 or 2021. Nonfinancial assets and liabilities or financial assets and liabilities measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. For the years ended December 31, 2022 and 2021, the Company recognized $211 million and $840 million, respectively, of unrealized gains in investment and other income related to fair value adjustments on equity securities primarily in our venture portfolio, based upon transaction of the same or similar security. There were no other significant fair value adjustments for these assets and liabilities recorded during the years ended December 31, 2022 or 2021. The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below: Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments which do not trade on a regular basis in active markets are classified as Level 2. Debt and Equity Securities. Fair values of debt securities and equity securities reported at fair value on a recurring basis are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs currently observable in the markets for similar securities. Inputs often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment to the prices obtained from the pricing service. Fair values of debt securities which do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2. Fair value estimates for Level 1 and Level 2 equity securities reported at fair value on a recurring basis are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices. The fair values of Level 3 investments in corporate bonds, which are not a significant portion of our investments, are estimated using valuation techniques relying heavily on management assumptions and qualitative observations. Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on such understanding. Assets Under Management. Assets under management consists of debt securities and other investments held to fund costs associated with the AARP Program and are priced and classified using the same methodologies as the Company’s investments in debt and equity securities. Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities. |
Schedule I (Policies)
Schedule I (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Condensed Financial Statements, Captions [Line Items] | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Basis of Presentation, Use of Estimates and Significant Accounting Policies Basis of Presentation The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. Use of Estimates These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues Premiums Premium revenues are primarily derived from risk-based arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs. Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios (MLRs) as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, falling below certain targets are required to rebate ratable portions of their premiums annually. Commercial premiums within the Company’s individual and small group markets are also subject to the ACA risk adjustment program. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star rating. Certain of the Company’s Medicaid business is also subject to state minimum MLR rebates. Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues for certain value-based arrangements at its Optum Health care delivery businesses. Under these value-based arrangements, the Company enters into agreements with health plans to stand ready to deliver, integrate, direct and control certain health care services for patients. In exchange, the Company receives a premium that is typically paid on a per-patient per-month basis. The Company considers these value-based arrangements to represent a single performance obligation where premium revenues are recognized in the period in which health care services are made available. The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model which apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis and encounter data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits. Products and Services For the Company’s Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, product revenues are reported on a gross basis. Services revenue includes a number of services and products sold through Optum. Optum Health’s service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers. Services revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period. As of December 31, 2022 and 2021, accounts receivables related to products and services were $7.1 billion and $5.4 billion, respectively. In 2022 and 2021, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2022 or 2021. For the years ended December 31, 2022, 2021 and 2020, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.5 billion, of which approximately half is expected to be recognized in the next three See Note 14 for disaggregation of revenue by segment and type. Medical Costs and Medical Costs Payable The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2022. Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, care activity and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes, and business mix changes related to products, customers and geography. In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months. Cost of Products Sold The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services. Cash, Cash Equivalents and Investments Cash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments. Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments, with certain exceptions, are measured at fair value with changes in fair value recognized in net earnings. The Company excludes unrealized gains and losses on investments in available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold. The Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings. New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Securities downgraded below policy minimums after purchase will be disposed of in accordance with the Company’s investment policy. Assets Under Management The Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program) and to AARP members and non-members under separate Medicare Advantage and Medicare Part D arrangements. The products and services under the AARP Program include supplemental Medicare benefits, hospital indemnity insurance, including insurance for individuals between 50 to 64 years of age, and other related products. Pursuant to the Company’s agreement with AARP, program assets are managed separately from the Company’s general investment portfolio and are used to pay costs associated with the AARP Program. These assets are invested at the Company’s discretion, within investment guidelines approved by AARP. The Company does not guarantee any rates of return on these investments and, upon any transfer of the AARP Program contract to another entity, the Company would transfer cash equal in amount to the fair value of these investments at the date of transfer to the entity. Because the purpose of these assets is to fund the medical costs payable, the rate stabilization fund (RSF) liabilities and other related liabilities associated with this AARP contract, assets under management are classified as current assets, consistent with the classification of these liabilities. Other Current Receivables Other current receivables include amounts due from pharmaceutical manufacturers for rebates and Medicare Part D drug discounts, accrued interest and other miscellaneous amounts due to the Company. The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and unaffiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2022 and 2021, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $8.2 billion and $7.2 billion, respectively. As of December 31, 2022 and 2021, the Company’s Medicare Part D receivables amounted to $1.3 billion and $3.4 billion, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include pharmaceutical drug and supplies inventory of $3.5 billion and $2.9 billion as of December 31, 2022 and 2021, respectively. Property, Equipment and Capitalized Software Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development. The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life. Operating Leases The Company leases facilities and equipment under long-term operating leases which are non-cancelable and expire on various dates. At the lease commencement date, lease right-of-use (ROU) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not implicit in a lease, the Company utilizes its incremental borrowing rate for a period closely matching the lease term. The Company’s ROU assets are included in other assets, and lease liabilities are included in other current liabilities and other liabilities in the Company’s Consolidated Balance Sheet Goodwill To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs impairment tests. The Company may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill. There was no impairment of goodwill during the years ended December 31, 2022, 2021 and 2020. Intangible Assets The Company’s intangible assets are subject to impairment tests when events or circumstances indicate an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the years ended December 31, 2022, 2021 and 2020. Other Current Liabilities Other current liabilities include health savings account deposits ($13.5 billion and $11.4 billion as of December 31, 2022 and 2021, respectively), accruals for premium rebates payable, the RSF associated with the AARP Program, the current portion of future policy benefits and customer balances. Policy Acquisition Costs The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred. Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2022 and 2021: (in millions) 2022 2021 Redeemable noncontrolling interests, beginning of period $ 1,434 $ 2,211 Net earnings 113 87 Acquisitions 3,108 28 Redemptions (176) (1,338) Distributions (82) (255) Fair value and other adjustments 500 701 Redeemable noncontrolling interests, end of period $ 4,897 $ 1,434 Share-Based Compensation The Company recognizes compensation expense for share-based awards, including stock options and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over four four |
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] | Redeemable Noncontrolling Interests Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside of the Company’s control are classified as temporary equity. These interests primarily relate to put options on unowned shares, which are typically redeemable at fair value after a certain time period. The Company accretes changes in the redemption value to the earliest redemption date utilizing the interest method. If all interests were currently redeemable, the difference between the carrying value and the estimated redemption value is not material. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2022 and 2021: (in millions) 2022 2021 Redeemable noncontrolling interests, beginning of period $ 1,434 $ 2,211 Net earnings 113 87 Acquisitions 3,108 28 Redemptions (176) (1,338) Distributions (82) (255) Fair value and other adjustments 500 701 Redeemable noncontrolling interests, end of period $ 4,897 $ 1,434 |
Parent Company [Member] | |
Condensed Financial Statements, Captions [Line Items] | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Basis of Presentation UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of the Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” |
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] | Subsidiary Transactions Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries. |
Basis of Presentation, Uses o_3
Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Property, Plant and Equipment [Table Text Block] | A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2022 December 31, 2021 Land and improvements $ 697 $ 502 Buildings and improvements 5,519 4,882 Computer equipment 2,093 1,851 Furniture and fixtures 2,113 2,014 Less accumulated depreciation (4,499) (3,857) Property and equipment, net 5,923 5,392 Capitalized software 6,636 5,712 Less accumulated amortization (2,431) (2,135) Capitalized software, net 4,205 3,577 Total property, equipment and capitalized software, net $ 10,128 $ 8,969 |
Redeemable Noncontrolling Interest [Table Text Block] | The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2022 and 2021: (in millions) 2022 2021 Redeemable noncontrolling interests, beginning of period $ 1,434 $ 2,211 Net earnings 113 87 Acquisitions 3,108 28 Redemptions (176) (1,338) Distributions (82) (255) Fair value and other adjustments 500 701 Redeemable noncontrolling interests, end of period $ 4,897 $ 1,434 |
Useful Life [Member] | |
Property, Plant and Equipment [Table Text Block] | The useful lives for property, equipment and capitalized software are: Furniture, fixtures and equipment 3 to 10 years Buildings 35 to 40 years Capitalized software 3 to 5 years |
Investments (Tables)
Investments (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Short-Term and Long-Term Investments [Table Text Block] | A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000 December 31, 2021 Debt securities - available-for-sale: U.S. government and agency obligations $ 3,206 $ 23 $ (31) $ 3,198 State and municipal obligations 6,829 297 (20) 7,106 Corporate obligations 20,947 372 (145) 21,174 U.S. agency mortgage-backed securities 5,868 88 (55) 5,901 Non-U.S. agency mortgage-backed securities 2,819 42 (23) 2,838 Total debt securities - available-for-sale 39,669 822 (274) 40,217 Debt securities - held-to-maturity: U.S. government and agency obligations 511 2 (2) 511 State and municipal obligations 30 2 — 32 Corporate obligations 100 — — 100 Total debt securities - held-to-maturity 641 4 (2) 643 Total debt securities $ 40,310 $ 826 $ (276) $ 40,860 |
Investments by Contractual Maturity [Table Text Block] | The amortized cost and fair value of debt securities as of December 31, 2022, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,713 $ 4,682 $ 374 $ 369 Due after one year through five years 13,135 12,404 265 256 Due after five years through ten years 12,210 10,897 37 36 Due after ten years 5,412 4,968 20 18 U.S. agency mortgage-backed securities 7,379 6,586 — — Non-U.S. agency mortgage-backed securities 3,077 2,784 — — Total debt securities $ 45,926 $ 42,321 $ 696 $ 679 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value | The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross December 31, 2022 U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664) December 31, 2021 U.S. government and agency obligations $ 1,976 $ (18) $ 249 $ (13) $ 2,225 $ (31) State and municipal obligations 1,386 (19) 31 (1) 1,417 (20) Corporate obligations 9,357 (130) 376 (15) 9,733 (145) U.S. agency mortgage-backed securities 3,078 (52) 116 (3) 3,194 (55) Non-U.S. agency mortgage-backed securities 1,321 (18) 114 (5) 1,435 (23) Total debt securities - available-for-sale $ 17,118 $ (237) $ 886 $ (37) $ 18,004 $ (274) |
Fair Value (Tables)
Fair Value (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 % December 31, 2021 Cash and cash equivalents $ 21,359 $ 16 $ — $ 21,375 Debt securities - available-for-sale: U.S. government and agency obligations 3,017 181 — 3,198 State and municipal obligations — 7,106 — 7,106 Corporate obligations 40 20,916 218 21,174 U.S. agency mortgage-backed securities — 5,901 — 5,901 Non-U.S. agency mortgage-backed securities — 2,838 — 2,838 Total debt securities - available-for-sale 3,057 36,942 218 40,217 Equity securities 2,090 23 64 2,177 Assets under management 1,972 2,376 101 4,449 Total assets at fair value $ 28,478 $ 39,357 $ 383 $ 68,218 Percentage of total assets at fair value 42 % 57 % 1 % 100 % |
Fair Value Measurements, Nonrecurring [Table Text Block] | The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823 December 31, 2021 Debt securities - held-to-maturity $ 534 $ 102 $ 7 $ 643 $ 641 Long-term debt and other financing obligations $ — $ 52,583 $ — $ 52,583 $ 46,003 |
Property, Plant, and Capitali_2
Property, Plant, and Capitalized Software (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment [Table Text Block] | A summary of property, equipment and capitalized software is as follows: (in millions) December 31, 2022 December 31, 2021 Land and improvements $ 697 $ 502 Buildings and improvements 5,519 4,882 Computer equipment 2,093 1,851 Furniture and fixtures 2,113 2,014 Less accumulated depreciation (4,499) (3,857) Property and equipment, net 5,923 5,392 Capitalized software 6,636 5,712 Less accumulated amortization (2,431) (2,135) Capitalized software, net 4,205 3,577 Total property, equipment and capitalized software, net $ 10,128 $ 8,969 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill [Line Items] | |
Schedule of Goodwill [Table Text Block] | Changes in the carrying amount of goodwill, by reportable segment, were as follows: (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Consolidated Balance at January 1, 2021 $ 27,785 $ 19,844 $ 8,173 $ 15,535 $ 71,337 Acquisitions 60 4,648 96 — 4,804 Foreign currency effects and other adjustments, net (456) (268) 350 28 (346) Balance at December 31, 2021 27,389 24,224 8,619 15,563 75,795 Acquisitions 19 5,158 8,623 3,910 17,710 Foreign currency effects and other adjustments, net (13) (144) 2 2 (153) Balance at December 31, 2022 $ 27,395 $ 29,238 $ 17,244 $ 19,475 $ 93,352 |
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] | The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows: December 31, 2022 December 31, 2021 (in millions) Gross Carrying Value Accumulated Amortization Net Carrying Value Gross Carrying Value Accumulated Amortization Net Carrying Value Customer-related $ 16,303 $ (5,179) $ 11,124 $ 13,011 $ (4,697) $ 8,314 Trademarks and technology 2,398 (704) 1,694 1,630 (739) 891 Trademarks and other indefinite-lived 661 — 661 617 — 617 Other 1,176 (254) 922 422 (200) 222 Total $ 20,538 $ (6,137) $ 14,401 $ 15,680 $ (5,636) $ 10,044 |
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] | The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations consisted of the following by year of acquisition: 2022 2021 (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 3,927 15 years $ 484 9 years Trademarks and technology 1,058 6 years 147 5 years Other 776 13 years 29 11 years Total acquired finite-lived intangible assets $ 5,761 13 years $ 660 8 years |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows: (in millions) 2023 $ 1,562 2024 1,478 2025 1,360 2026 1,206 2027 1,154 |
Medical Costs Payable (Tables)
Medical Costs Payable (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Insurance [Abstract] | |
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] | The following table shows the components of the change in medical costs payable for the years ended December 31: (in millions) 2022 2021 2020 Medical costs payable, beginning of period $ 24,483 $ 21,872 $ 21,690 Acquisitions 308 88 316 Reported medical costs: Current year 211,252 188,631 160,276 Prior years (410) (1,720) (880) Total reported medical costs 210,842 186,911 159,396 Medical payments: Payments for current year (184,049) (165,524) (139,974) Payments for prior years (22,528) (18,864) (19,556) Total medical payments (206,577) (184,388) (159,530) Medical costs payable, end of period $ 29,056 $ 24,483 $ 21,872 |
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] | The following is information about incurred and paid medical cost development as of December 31, 2022: Net Incurred Medical Costs (in millions) For the Years Ended December 31, Year 2021 2022 2021 $ 188,631 $ 188,407 2022 211,252 Total $ 399,659 Net Cumulative Medical Payments (in millions) For the Years Ended December 31, Year 2021 2022 2021 $ (165,524) $ (186,944) 2022 (184,049) Total (370,993) Net remaining outstanding liabilities prior to 2021 390 Total medical costs payable $ 29,056 |
Short-Term Borrowings and Lon_2
Short-Term Borrowings and Long-Term Debt (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Debt Instrument [Line Items] | |
Short-Term Borrowings and Long-Term Debt [Table Text Block] | Short-term borrowings and senior unsecured long-term debt consisted of the following: Carrying Value As of December 31, (in millions, except percentages) 2022 2021 Commercial paper $ 800 $ — $1,100 million 2.875% notes due March 2022 — 1,097 $1,000 million 3.350% notes due July 2022 — 999 $900 million 2.375% notes due October 2022 — 899 $15 million 0.000% notes due November 2022 — 14 $625 million 2.750% notes due February 2023 622 632 $750 million 2.875% notes due March 2023 746 768 $750 million 3.500% notes due June 2023 750 749 $750 million 3.500% notes due February 2024 749 748 $1,000 million 0.550% notes due May 2024 998 996 $750 million 2.375% notes due August 2024 749 748 $500 million 5.000% notes due October 2024 499 — $2,000 million 3.750% notes due July 2025 1,995 1,994 $750 million 5.150% notes due October 2025 747 — $300 million 3.700% notes due December 2025 299 299 $500 million 1.250% notes due January 2026 498 497 $1,000 million 3.100% notes due March 2026 998 997 $1,000 million 1.150% notes due May 2026 893 972 $750 million 3.450% notes due January 2027 748 747 $625 million 3.375% notes due April 2027 622 621 $600 million 3.700% notes due May 2027 597 — $950 million 2.950% notes due October 2027 943 942 $1,000 million 5.250% notes due February 2028 1,008 — $1,150 million 3.850% notes due June 2028 1,145 1,144 $850 million 3.875% notes due December 2028 845 844 $900 million 4.000% notes due May 2029 849 — $1,000 million 2.875% notes due August 2029 886 1,023 $1,250 million 5.300% notes due February 2030 1,269 — $1,250 million 2.000% notes due May 2030 1,237 1,235 $1,500 million 2.300% notes due May 2031 1,256 1,482 $1,500 million 4.200% notes due May 2032 1,393 — $2,000 million 5.350% notes due February 2033 2,037 — $1,000 million 4.625% notes due July 2035 993 993 $850 million 5.800% notes due March 2036 840 839 $500 million 6.500% notes due June 2037 493 492 $650 million 6.625% notes due November 2037 642 642 $1,100 million 6.875% notes due February 2038 1,079 1,078 $1,250 million 3.500% notes due August 2039 1,242 1,242 $1,000 million 2.750% notes due May 2040 967 966 $300 million 5.700% notes due October 2040 296 296 $350 million 5.950% notes due February 2041 346 346 $1,500 million 3.050% notes due May 2041 1,483 1,483 Carrying Value As of December 31, (in millions, except percentages) 2022 2021 $600 million 4.625% notes due November 2041 590 589 $502 million 4.375% notes due March 2042 486 485 $625 million 3.950% notes due October 2042 609 608 $750 million 4.250% notes due March 2043 736 736 $2,000 million 4.750% notes due July 2045 1,975 1,974 $750 million 4.200% notes due January 2047 739 739 $725 million 4.250% notes due April 2047 718 718 $950 million 3.750% notes due October 2047 935 934 $1,350 million 4.250% notes due June 2048 1,331 1,330 $1,100 million 4.450% notes due December 2048 1,087 1,087 $1,250 million 3.700% notes due August 2049 1,236 1,236 $1,250 million 2.900% notes due May 2050 1,210 1,209 $2,000 million 3.250% notes due May 2051 1,971 1,970 $2,000 million 4.750% notes due May 2052 1,965 — $2,000 million 5.875% notes due February 2053 1,968 — $1,250 million 3.875% notes due August 2059 1,228 1,228 $1,000 million 3.125% notes due May 2060 966 965 $1,000 million 4.950% notes due May 2062 981 — $1,500 million 6.050% notes due February 2063 1,466 — Total short-term borrowings and long-term debt $ 56,756 $ 44,632 |
Schedule of Maturities of Long-term Debt [Table Text Block] | Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2023 $ 3,117 2024 3,136 2025 3,186 2026 2,636 2027 3,061 Thereafter 43,638 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Contingency [Line Items] | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | The components of the provision for income taxes for the years ended December 31 are as follows: (in millions) 2022 2021 2020 Current Provision: Federal $ 4,842 $ 3,451 $ 4,098 State and local 855 481 392 Foreign 680 516 491 Total current provision 6,377 4,448 4,981 Deferred (benefit) provision (673) 130 (8) Total provision for income taxes $ 5,704 $ 4,578 $ 4,973 |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows: (in millions, except percentages) 2022 2021 2020 Tax provision at the U.S. federal statutory rate $ 5,532 21.0 % $ 4,685 21.0 % $ 4,356 21.0 % State income taxes, net of federal benefit 621 2.4 419 1.9 315 1.5 Share-based awards - excess tax benefit (110) (0.4) (100) (0.4) (130) (0.6) Non-deductible compensation 150 0.6 144 0.6 134 0.7 Health insurance tax — — — — 626 3.0 Foreign rate differential (265) (1.0) (246) (1.1) (164) (0.8) Other, net (224) (0.9) (324) (1.5) (164) (0.8) Provision for income taxes $ 5,704 21.7 % $ 4,578 20.5 % $ 4,973 24.0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The components of deferred income tax assets and liabilities as of December 31 are as follows: (in millions) 2022 2021 Deferred income tax assets: Accrued expenses and allowances $ 707 $ 723 U.S. federal and state net operating loss carryforwards 540 287 Share-based compensation 154 117 Nondeductible liabilities 341 296 Non-U.S. tax loss carryforwards 631 435 Lease liability 972 1,284 Net unrealized losses on investments 829 — Other-domestic 291 228 Other-non-U.S. 423 376 Subtotal 4,888 3,746 Less: valuation allowances (291) (198) Total deferred income tax assets 4,597 3,548 Deferred income tax liabilities: U.S. federal and state intangible assets (3,520) (2,658) Non-U.S. goodwill and intangible assets (550) (512) Capitalized software (548) (833) Depreciation and amortization (520) (349) Prepaid expenses (275) (256) Outside basis in partnerships (653) (565) Lease right-of-use asset (958) (1,267) Net unrealized gains on investments — (125) Other-non-U.S. (342) (248) Total deferred income tax liabilities (7,366) (6,813) Net deferred income tax liabilities $ (2,769) $ (3,265) |
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] | A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows: (in millions) 2022 2021 2020 Gross unrecognized tax benefits, beginning of period $ 2,310 $ 1,829 $ 1,423 Gross increases: Current year tax positions 586 538 416 Prior year tax positions 206 10 120 Gross decreases: Prior year tax positions (21) (47) (130) Statute of limitations lapses — (20) — Gross unrecognized tax benefits, end of period $ 3,081 $ 2,310 $ 1,829 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Shareholders' Equity [Abstract] | |
Share Repurchase Activity | A summary of common share repurchases for the years ended December 31, 2022 and 2021 is as follows: Years Ended December 31, (in millions, except per share data) 2022 2021 Common share repurchases, shares 14 13 Common share repurchases, average price per share $ 501.67 $ 389.92 Common share repurchases, aggregate cost $ 7,000 $ 5,000 Board authorized shares remaining 31 45 |
Dividends Declared | The following table provides details of the Company’s 2022 dividend payments: Payment Date Amount per Share Total Amount Paid (in millions) March 22 $ 1.45 $ 1,363 June 28 1.65 1,545 September 20 1.65 1,542 December 13 1.65 1,541 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock Option Activity [Table Text Block] | Stock option activity for the year ended December 31, 2022 is summarized in the table below: Shares Weighted- Weighted- Aggregate (in millions) (in years) (in millions) Outstanding at beginning of period 25 $ 241 Granted 4 459 Exercised (5) 215 Forfeited (1) 356 Outstanding at end of period 23 281 5.8 $ 5,914 Exercisable at end of period 13 213 4.4 4,170 Vested and expected to vest, end of period 23 278 5.7 5,854 |
Restricted Share Activity [Table Text Block] | Restricted share activity for the year ended December 31, 2022 is summarized in the table below: (shares in millions) Shares Weighted-Average Nonvested at beginning of period 4 $ 303 Granted 2 483 Vested (2) 287 Nonvested at end of period 4 401 |
Other Share-Based Compensation Data [Table Text Block] | Other Share-Based Compensation Data (in millions, except per share amounts) For the Years Ended December 31, 2022 2021 2020 Stock Options Weighted-average grant date fair value of shares granted, per share $ 116 $ 71 $ 54 Total intrinsic value of stock options exercised 1,419 1,519 1,736 Restricted Shares Weighted-average grant date fair value of shares granted, per share 483 352 303 Total fair value of restricted shares vested $ 760 $ 560 $ 574 Employee Stock Purchase Plan Number of shares purchased 1 1 1 Share-Based Compensation Items Share-based compensation expense, before tax $ 925 $ 800 $ 679 Share-based compensation expense, net of tax effects 836 719 619 Income tax benefit realized from share-based award exercises 207 173 208 (in millions, except years) December 31, 2022 Unrecognized compensation expense related to share awards $ 1,165 Weighted-average years to recognize compensation expense 1.3 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The principal assumptions the Company used in calculating grant-date fair value for stock options were as follows: For the Years Ended December 31, 2022 2021 2020 Risk-free interest rate 1.9% - 4.3% 0.7% - 1.2% 0.2% - 1.4% Expected volatility 30.6% -30.8% 29.2% - 29.8% 22.2% - 29.5% Expected dividend yield 1.2% 1.3% - 1.5% 1.4% - 1.7% Forfeiture rate 5.0% 5.0% 5.0% Expected life in years 4.7 4.8 5.1 |
Commitments and Contingencies_2
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | As of December 31, 2022, future minimum annual lease payments under all non-cancelable operating leases were as follows: (in millions) Future Minimum Lease Payments 2023 $ 997 2024 858 2025 702 2026 578 2027 475 Thereafter 2,028 Total future minimum lease payments 5,638 Less imputed interest (808) Total $ 4,830 |
Business Combinations (Tables)
Business Combinations (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | Acquired assets (liabilities) at acquisition date were: (in millions) Change Other Acquisitions Total Cash and cash equivalents $ 222 $ 523 $ 745 Accounts receivable and other current assets 925 696 1,621 Assets held-for-sale 2,310 — 2,310 Property, equipment and other long-term assets 254 1,882 2,136 Other intangible assets 4,050 1,764 5,814 Total identifiable assets acquired 7,761 4,865 12,626 Medical costs payable — (308) (308) Accounts payable and other current liabilities (1,017) (843) (1,860) Liabilities held-for-sale (101) — (101) Other long-term liabilities (1,193) (713) (1,906) Total identifiable liabilities acquired (2,311) (1,864) (4,175) Total net identifiable assets 5,450 3,001 8,451 Goodwill 8,496 9,214 17,710 Redeemable noncontrolling interests — (3,108) (3,108) Nonredeemable noncontrolling interests — (370) (370) Net assets acquired $ 13,946 $ 8,737 $ 22,683 |
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] | The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations consisted of the following by year of acquisition: 2022 2021 (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 3,927 15 years $ 484 9 years Trademarks and technology 1,058 6 years 147 5 years Other 776 13 years 29 11 years Total acquired finite-lived intangible assets $ 5,761 13 years $ 660 8 years |
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combinations | The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired consisted of the following: Change Other Acquisitions Total (in millions, except years) Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Fair Value Weighted-Average Useful Life Customer-related $ 3,063 15 years $ 864 13 years $ 3,927 15 years Trademarks and technology 977 6 years 81 4 years 1,058 6 years Other 10 1 year 766 13 years 776 13 years Total acquired finite-lived intangible assets $ 4,050 13 years $ 1,711 13 years $ 5,761 13 years |
Segment Financial Information_2
Segment Financial Information (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
Segment Financial Information [Table Text Block] | The following table presents the reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated 2022 Revenues - unaffiliated customers: Premiums $ 238,783 $ 18,374 $ — $ — $ — $ 18,374 $ — $ 257,157 Products — 72 180 37,172 — 37,424 — 37,424 Services 10,035 10,917 4,996 1,603 — 17,516 — 27,551 Total revenues - unaffiliated customers 248,818 29,363 5,176 38,775 — 73,314 — 322,132 Total revenues - affiliated customers — 40,883 9,288 60,936 (2,760) 108,347 (108,347) — Investment and other income 923 928 117 62 — 1,107 — 2,030 Total revenues $ 249,741 $ 71,174 $ 14,581 $ 99,773 $ (2,760) $ 182,768 $ (108,347) $ 324,162 Earnings from operations $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ — $ 28,435 Interest expense — — — — — — (2,092) (2,092) Earnings before income taxes $ 14,379 $ 6,032 $ 3,588 $ 4,436 $ — $ 14,056 $ (2,092) $ 26,343 Total assets $ 107,094 $ 68,950 $ 31,090 $ 47,476 $ — $ 147,516 $ (8,905) $ 245,705 Purchases of property, equipment and capitalized software 799 997 698 308 — 2,003 — 2,802 Depreciation and amortization 973 943 841 643 — 2,427 — 3,400 2021 Revenues - unaffiliated customers: Premiums $ 212,381 $ 13,852 $ — $ — $ — $ 13,852 $ — $ 226,233 Products — 32 159 34,246 — 34,437 — 34,437 Services 9,661 9,894 3,936 1,112 — 14,942 — 24,603 Total revenues - unaffiliated customers 222,042 23,778 4,095 35,358 — 63,231 — 285,273 Total revenues - affiliated customers — 29,234 7,867 55,779 (2,013) 90,867 (90,867) — Investment and other income 857 1,053 237 177 — 1,467 — 2,324 Total revenues $ 222,899 $ 54,065 $ 12,199 $ 91,314 $ (2,013) $ 155,565 $ (90,867) $ 287,597 Earnings from operations $ 11,975 $ 4,462 $ 3,398 $ 4,135 $ — $ 11,995 $ — $ 23,970 Interest expense — — — — — — (1,660) (1,660) Earnings before income taxes $ 11,975 $ 4,462 $ 3,398 $ 4,135 $ — $ 11,995 $ (1,660) $ 22,310 Total assets $ 102,967 $ 60,474 $ 16,868 $ 40,181 $ — $ 117,523 $ (8,284) $ 212,206 Purchases of property, equipment and capitalized software 795 791 567 301 — 1,659 — 2,454 Depreciation and amortization 1,004 818 684 597 — 2,099 — 3,103 2020 Revenues - unaffiliated customers: Premiums $ 191,679 $ 9,799 $ — $ — $ — $ 9,799 $ — $ 201,478 Products — 33 135 33,977 — 34,145 — 34,145 Services 8,464 6,815 3,687 1,050 — 11,552 — 20,016 Total revenues - unaffiliated customers 200,143 16,647 3,822 35,027 — 55,496 — 255,639 Total revenues - affiliated customers — 22,481 6,941 52,420 (1,800) 80,042 (80,042) — Investment and other income 732 680 39 51 — 770 — 1,502 Total revenues $ 200,875 $ 39,808 $ 10,802 $ 87,498 $ (1,800) $ 136,308 $ (80,042) $ 257,141 Earnings from operations $ 12,359 $ 3,434 $ 2,725 $ 3,887 $ — $ 10,046 $ — $ 22,405 Interest expense — — — — — — (1,663) (1,663) Earnings before income taxes $ 12,359 $ 3,434 $ 2,725 $ 3,887 $ — $ 10,046 $ (1,663) $ 20,742 Total assets $ 98,229 $ 52,073 $ 15,425 $ 39,280 $ — $ 106,778 $ (7,718) $ 197,289 Purchases of property, equipment and capitalized software 687 715 461 188 — 1,364 — 2,051 Depreciation and amortization 920 703 670 598 — 1,971 — 2,891 |
Schedule I (Tables)
Schedule I (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Condensed Financial Statements, Captions [Line Items] | |
Schedule of Maturities of Long-term Debt [Table Text Block] | Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2023 $ 3,117 2024 3,136 2025 3,186 2026 2,636 2027 3,061 Thereafter 43,638 |
Parent Company [Member] | |
Condensed Financial Statements, Captions [Line Items] | |
Condensed Balance Sheet [Table Text Block] | Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Balance Sheets (in millions, except per share data) December 31, December 31, Assets Current assets: Cash and cash equivalents $ 266 $ 2,167 Other current assets 753 503 Total current assets 1,019 2,670 Equity in net assets of subsidiaries 136,562 116,907 Long-term notes receivable from subsidiaries 6,201 5,680 Other assets 504 32 Total assets $ 144,286 $ 125,289 Liabilities and shareholders’ equity Current liabilities: Accounts payable and accrued liabilities $ 835 $ 605 Current portion of notes payable to subsidiaries 8,699 8,105 Short-term borrowings and current maturities of long-term debt 2,918 3,009 Total current liabilities 12,452 11,719 Long-term debt, less current maturities 53,838 41,623 Other liabilities 224 187 Total liabilities 66,514 53,529 Commitments and contingencies (Note 4) Shareholders’ equity: Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding — — Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding 9 10 Retained earnings 86,156 77,134 Accumulated other comprehensive loss (8,393) (5,384) Total UnitedHealth Group shareholders’ equity 77,772 71,760 Total liabilities and shareholders’ equity $ 144,286 $ 125,289 |
Condensed Statement of Comprehensive Income [Table Text Block] | Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Comprehensive Income For the Years Ended December 31, (in millions) 2022 2021 2020 Revenues: Investment and other income $ 255 $ 494 $ 194 Total revenues 255 494 194 Operating costs: Operating costs 121 40 27 Interest expense 2,110 1,583 1,594 Total operating costs 2,231 1,623 1,621 Loss before income taxes (1,976) (1,129) (1,427) Benefit for income taxes 429 231 300 Loss of parent company (1,547) (898) (1,127) Equity in undistributed income of subsidiaries 21,667 18,183 16,530 Net earnings 20,120 17,285 15,403 Other comprehensive loss (3,009) (1,570) (236) Comprehensive income $ 17,111 $ 15,715 $ 15,167 |
Condensed Cash Flow Statement [Table Text Block] | Condensed Financial Information of Registrant (Parent Company Only) UnitedHealth Group Condensed Statements of Cash Flows For the Years Ended December 31, (in millions) 2022 2021 2020 Operating activities Cash flows from operating activities $ 14,754 $ 11,439 $ 8,842 Investing activities Issuances of notes to subsidiaries (567) (444) (628) Repayments of notes to subsidiaries 281 37 1,089 Cash paid for acquisitions (20,728) (4,953) (7,706) Return of capital to parent company 1,424 245 943 Capital contributions to subsidiaries (570) (747) (43) Cash received from dispositions 2,787 — 143 Cash flows used for investing activities (17,373) (5,862) (6,202) Financing activities Common stock repurchases (7,000) (5,000) (4,250) Proceeds from common stock issuances 1,253 1,355 1,440 Cash dividends paid (5,991) (5,280) (4,584) Proceed from (repayments of) short-term borrowings, net 732 (1,302) 872 Proceeds from issuance of long-term debt 14,819 6,933 4,864 Repayments of long-term debt (3,015) (3,150) (3,150) Proceeds from notes from subsidiaries 594 3,223 2,818 Other, net (674) (447) (438) Cash flows from (used for) financing activities 718 (3,668) (2,428) (Decrease) increase in cash and cash equivalents (1,901) 1,909 212 Cash and cash equivalents, beginning of period 2,167 258 46 Cash and cash equivalents, end of period $ 266 $ 2,167 $ 258 Supplemental cash flow disclosures Cash paid for interest $ 1,969 $ 1,575 $ 1,633 Cash paid for income taxes 4,298 3,050 4,185 |
Schedule of Maturities of Long-term Debt [Table Text Block] | Maturities of short-term borrowings and long-term debt for the years ending December 31 are as follows: (in millions) 2023 $ 2,925 2024 3,000 2025 3,050 2026 2,500 2027 2,925 Thereafter 43,502 |
Basis of Presentation, Uses o_4
Basis of Presentation, Uses of Estimates and Significant Accounting Policies (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounts Receivable, after Allowance for Credit Loss, Current | $ 17,681 | $ 14,216 | |
Revenue, Remaining Performance Obligation, Amount | 12,500 | ||
Other current receivables | 12,769 | 13,866 | |
Inventory, Net | $ 3,500 | 2,900 | |
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] | Other Liabilities | ||
Accounts payable and accrued liabilities | $ 27,715 | 24,643 | |
Other Liabilities, Current | $ 26,281 | 22,975 | |
Number Of Days Notice Required To Cancel Health Insurance Contract | 30 days | ||
Goodwill, Impairment Loss | $ 0 | 0 | $ 0 |
Impairment of Intangible Assets (Excluding Goodwill) | $ 0 | 0 | $ 0 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |||
Revenue, Remaining Performance Obligation, Percentage | 50% | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period | 3 years | ||
Other Current Liabilities [Member] | |||
Health savings account deposits | $ 13,500 | 11,400 | |
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||
Employee Stock Purchase Plan (ESPP) [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date | 10% | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | ||
Share-based Compensation Arrangement by Share-based Payment Plan Award, Options, Award Exercisable Period | 10 years | ||
Health Insurance Product Line [Member] | |||
Short-duration Insurance Contracts, Historical Claims Duration, First 90 Days | 0.90 | ||
Products and services [Member] | |||
Accounts Receivable, after Allowance for Credit Loss, Current | $ 7,100 | 5,400 | |
Pharmaceutical Manufacturer Rebates Receivable [Member] | |||
Other current receivables | 8,200 | 7,200 | |
Medicare Part D Receivables [Member] | |||
Other current receivables | $ 1,300 | $ 3,400 |
Basis of Presentation, Uses o_5
Basis of Presentation, Uses of Estimates and Significant Accounting Policies Useful lives for property, equipment and capitalized software (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Furniture, Fixtures and equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 3 years |
Furniture, Fixtures and equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 10 years |
Buildings [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 35 years |
Buildings [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 40 years |
Capitalized software [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 3 years |
Capitalized software [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Useful Life | 5 years |
Basis of Presentation, Uses o_6
Basis of Presentation, Uses of Estimates and Significant Accounting Policies Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Noncontrolling Interest [Line Items] | |||
Redeemable noncontrolling interest, beginning of period | $ 1,434 | ||
Acquisitions | 374 | $ 407 | $ 40 |
Distributions | (387) | (319) | (277) |
Fair value and other adjustments | (114) | 995 | 197 |
Redeemable Noncontrolling Interest, end of period | 4,897 | 1,434 | |
Redeemable Noncontrolling Interests [Member] | |||
Noncontrolling Interest [Line Items] | |||
Redeemable noncontrolling interest, beginning of period | 1,434 | 2,211 | |
Net earnings | 113 | 87 | |
Acquisitions | 3,108 | 28 | |
Redemptions | (176) | (1,338) | |
Distributions | (82) | (255) | |
Fair value and other adjustments | 500 | 701 | |
Redeemable Noncontrolling Interest, end of period | $ 4,897 | $ 1,434 | $ 2,211 |
Investments (Narrative) (Detail
Investments (Narrative) (Details) $ in Billions | Dec. 31, 2022 USD ($) positions | Dec. 31, 2021 USD ($) |
Investments [Abstract] | ||
Equity Securities, FV-NI and without Readily Determinable Fair Value | $ 3.7 | $ 3.5 |
Equity Method Investments | $ 1.5 | $ 1.3 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | positions | 35,000 | |
Total number of security positions | 41,000 |
Investments (Short-Term and Lon
Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | $ 45,926 | $ 39,669 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 59 | 822 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (3,664) | (274) |
Debt Securities, Available-for-sale | 42,321 | 40,217 |
Held-to-maturity securities, Amortized Cost | 696 | 641 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 4 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (17) | (2) |
Debt Securities, Held-to-maturity, Fair Value | 679 | 643 |
Total investments, Amortized Cost | 46,622 | 40,310 |
Total investments, Gross Unrealized Gains | 59 | 826 |
Total investments, Gross Unrealized Losses | (3,681) | (276) |
Investments, Fair Value Disclosure | 43,000 | 40,860 |
Debt Securities - held-to-maturity | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale | 42,321 | 40,217 |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 4,093 | 3,206 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 1 | 23 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (285) | (31) |
Debt Securities, Available-for-sale | 3,809 | 3,198 |
Held-to-maturity securities, Amortized Cost | 578 | 511 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 2 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (14) | (2) |
Debt Securities, Held-to-maturity, Fair Value | 564 | 511 |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 7,702 | 6,829 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 25 | 297 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (479) | (20) |
Debt Securities, Available-for-sale | 7,248 | 7,106 |
Held-to-maturity securities, Amortized Cost | 29 | 30 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 2 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | (3) | 0 |
Debt Securities, Held-to-maturity, Fair Value | 26 | 32 |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 23,675 | 20,947 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 17 | 372 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (1,798) | (145) |
Debt Securities, Available-for-sale | 21,894 | 21,174 |
Held-to-maturity securities, Amortized Cost | 89 | 100 |
Securities, Held to maturity, Unrecognized Holding Gain | 0 | 0 |
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | 0 | 0 |
Debt Securities, Held-to-maturity, Fair Value | 89 | 100 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 7,379 | 5,868 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 15 | 88 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (808) | (55) |
Debt Securities, Available-for-sale | 6,586 | 5,901 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Debt Securities, Available-for-sale, Amortized Cost | 3,077 | 2,819 |
Securities, Available for sale Debt Securities, Gross Unrealized Gains | 1 | 42 |
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | (294) | (23) |
Debt Securities, Available-for-sale | $ 2,784 | $ 2,838 |
Investments (Amortized Cost and
Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule of Investments [Line Items] | ||
Due in one year or less, Amortized Cost | $ 4,713 | |
Due after one year through five years, Amortized Cost | 13,135 | |
Due after five years through ten years, Amortized Cost | 12,210 | |
Due after ten years, Amortized Cost | 5,412 | |
Total debt securities - available-for-sale, Amortized Cost | 45,926 | $ 39,669 |
Due in one year or less, Fair Value | 4,682 | |
Due after one year through five years, Fair Value | 12,404 | |
Due after five years through ten years, Fair Value | 10,897 | |
Due after ten years, Fair Value | 4,968 | |
Debt Securities, Available-for-sale | 42,321 | 40,217 |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost | 374 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value | 369 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost | 265 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value | 256 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost | 37 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value | 36 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Amortized Cost | 20 | |
Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value | 18 | |
Debt Securities, Held-to-maturity | 696 | 641 |
Debt Securities, Held-to-maturity, Fair Value | 679 | 643 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 7,379 | |
Total debt securities - available-for-sale, Amortized Cost | 7,379 | 5,868 |
Debt Securities, Available-for-sale | 6,586 | 5,901 |
Mortgage-backed securities, Fair Value | 6,586 | |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Mortgage-backed securities, Amortized Cost | 3,077 | |
Total debt securities - available-for-sale, Amortized Cost | 3,077 | 2,819 |
Debt Securities, Available-for-sale | 2,784 | $ 2,838 |
Mortgage-backed securities, Fair Value | $ 2,784 |
Investments (Fair Value of Avai
Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Debt Securities - held-to-maturity | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | $ 24,899 | $ 17,118 |
Less Than 12 Months, Gross Unrealized Losses | (1,750) | (237) |
Greater Than 12 Months, Fair Value | 12,320 | 886 |
Greater Than 12 Months, Gross Unrealized Losses | (1,914) | (37) |
Total, Fair Value | 37,219 | 18,004 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (3,664) | (274) |
U.S. Government and Agency Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 2,007 | 1,976 |
Less Than 12 Months, Gross Unrealized Losses | (96) | (18) |
Greater Than 12 Months, Fair Value | 1,290 | 249 |
Greater Than 12 Months, Gross Unrealized Losses | (189) | (13) |
Total, Fair Value | 3,297 | 2,225 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (285) | (31) |
State and Municipal Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 4,630 | 1,386 |
Less Than 12 Months, Gross Unrealized Losses | (288) | (19) |
Greater Than 12 Months, Fair Value | 1,178 | 31 |
Greater Than 12 Months, Gross Unrealized Losses | (191) | (1) |
Total, Fair Value | 5,808 | 1,417 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (479) | (20) |
Corporate Obligations [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 13,003 | 9,357 |
Less Than 12 Months, Gross Unrealized Losses | (893) | (130) |
Greater Than 12 Months, Fair Value | 6,637 | 376 |
Greater Than 12 Months, Gross Unrealized Losses | (905) | (15) |
Total, Fair Value | 19,640 | 9,733 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (1,798) | (145) |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 3,561 | 3,078 |
Less Than 12 Months, Gross Unrealized Losses | (345) | (52) |
Greater Than 12 Months, Fair Value | 2,239 | 116 |
Greater Than 12 Months, Gross Unrealized Losses | (463) | (3) |
Total, Fair Value | 5,800 | 3,194 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | (808) | (55) |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Schedule of Investments [Line Items] | ||
Less Than 12 Months, Fair Value | 1,698 | 1,321 |
Less Than 12 Months, Gross Unrealized Losses | (128) | (18) |
Greater Than 12 Months, Fair Value | 976 | 114 |
Greater Than 12 Months, Gross Unrealized Losses | (166) | (5) |
Total, Fair Value | 2,674 | 1,435 |
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $ (294) | $ (23) |
Fair Value (Narrative) (Details
Fair Value (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value [Line Items] | ||
Transfers Into Level 3 | $ 0 | $ 0 |
Transfers out of Level 3 | 0 | 0 |
Equity Securities, FV-NI, Unrealized Gain | 211 | 840 |
Fair Value, Nonrecurring [Member] | ||
Fair Value [Line Items] | ||
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis | $ 0 | $ 0 |
Fair Value (Financial Assets an
Fair Value (Financial Assets and Liabilities, Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | $ 23,365 | $ 21,375 |
Debt Securities, Available-for-sale | 42,321 | 40,217 |
Equity Securities, FV-NI | 2,148 | 2,177 |
Assets under management | 4,087 | 4,449 |
Assets, Fair Value Disclosure | 71,921 | 68,218 |
Debt Securities - held-to-maturity | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 42,321 | 40,217 |
U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,809 | 3,198 |
State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 7,248 | 7,106 |
Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 21,894 | 21,174 |
U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,586 | 5,901 |
Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 2,784 | 2,838 |
Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 23,202 | 21,359 |
Equity Securities, FV-NI | 2,043 | 2,090 |
Assets under management | 1,788 | 1,972 |
Assets, Fair Value Disclosure | 30,545 | 28,478 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities - held-to-maturity | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,512 | 3,057 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 3,505 | 3,017 |
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 7 | 40 |
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 163 | 16 |
Equity Securities, FV-NI | 35 | 23 |
Assets under management | 2,203 | 2,376 |
Assets, Fair Value Disclosure | 41,018 | 39,357 |
Other Observable Inputs (Level 2) [Member] | Debt Securities - held-to-maturity | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 38,617 | 36,942 |
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 304 | 181 |
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 7,248 | 7,106 |
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 21,695 | 20,916 |
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 6,586 | 5,901 |
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 2,784 | 2,838 |
Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Equity Securities, FV-NI | 70 | 64 |
Assets under management | 96 | 101 |
Assets, Fair Value Disclosure | 358 | 383 |
Unobservable Inputs (Level 3) [Member] | Debt Securities - held-to-maturity | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 192 | 218 |
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 192 | 218 |
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 | $ 0 |
Fair Value (Financial Assets _2
Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | $ 679 | $ 643 |
Debt Securities, Held-to-maturity | 696 | 641 |
Debt and other financing obligations, carrying value | 56,756 | 44,632 |
Long-term debt and other financing obligations [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations, carrying value | 56,823 | 46,003 |
Fair Value, Nonrecurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 679 | 643 |
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 577 | 534 |
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 102 | 102 |
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Held-to-maturity, Fair Value | 0 | 7 |
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations | 53,626 | 52,583 |
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations | 0 | 0 |
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations | 53,626 | 52,583 |
Long-term debt and other financing obligations [Member] | Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt and other financing obligations | $ 0 | $ 0 |
Property, Plant, and Capitali_3
Property, Plant, and Capitalized Software (Narrative) (Details) - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | |||
Depreciation | $ 1.1 | $ 1 | $ 1 |
Capitalized Computer Software, Amortization | $ 1 | $ 0.9 | $ 0.8 |
Property, Plant, and Capitali_4
Property, Plant, and Capitalized Software Property Plant and Equipment Table (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Land and improvements | $ 697 | $ 502 |
Buildings and improvements | 5,519 | 4,882 |
Computer equipment | 2,093 | 1,851 |
Furniture and fixtures | 2,113 | 2,014 |
Less accumulated depreciation | (4,499) | (3,857) |
Property and equipment, net | 5,923 | 5,392 |
Capitalized software | 6,636 | 5,712 |
Less accumulated amortization | (2,431) | (2,135) |
Capitalized software, net | 4,205 | 3,577 |
Total property, equipment and capitalized software, net | $ 10,128 | $ 8,969 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Finite-Lived Intangible Assets [Line Items] | |||
Amortization of Intangible Assets | $ 1.3 | $ 1.2 | $ 1.1 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets Changes in the Carrying Amount of Goodwill by Reporting Segment (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Goodwill [Line Items] | ||
Goodwill, Beginning Balance | $ 75,795 | $ 71,337 |
Acquisitions | 17,710 | 4,804 |
Foreign currency effects and adjustments, net | (153) | (346) |
Goodwill, Ending Balance | 93,352 | 75,795 |
UnitedHealthcare | ||
Goodwill [Line Items] | ||
Goodwill, Beginning Balance | 27,389 | 27,785 |
Acquisitions | 19 | 60 |
Foreign currency effects and adjustments, net | (13) | (456) |
Goodwill, Ending Balance | 27,395 | 27,389 |
Optum Health | ||
Goodwill [Line Items] | ||
Goodwill, Beginning Balance | 24,224 | 19,844 |
Acquisitions | 5,158 | 4,648 |
Foreign currency effects and adjustments, net | (144) | (268) |
Goodwill, Ending Balance | 29,238 | 24,224 |
Optum Insight | ||
Goodwill [Line Items] | ||
Goodwill, Beginning Balance | 8,619 | 8,173 |
Acquisitions | 8,623 | 96 |
Foreign currency effects and adjustments, net | 2 | 350 |
Goodwill, Ending Balance | 17,244 | 8,619 |
Optum Rx | ||
Goodwill [Line Items] | ||
Goodwill, Beginning Balance | 15,563 | 15,535 |
Acquisitions | 3,910 | 0 |
Foreign currency effects and adjustments, net | 2 | 28 |
Goodwill, Ending Balance | $ 19,475 | $ 15,563 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets Gross carrying value, accumulated amortization and net carrying value of intangible assets (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Intangible Assets [Line Items] | ||
Intangible Assets, Gross (Excluding Goodwill) | $ 20,538 | $ 15,680 |
Finite-Lived Intangible Assets, Accumulated Amortization | (6,137) | (5,636) |
Intangible Assets, Net (Excluding Goodwill) | 14,401 | 10,044 |
Customer-Related Intangible Assets [Member] | ||
Intangible Assets [Line Items] | ||
Intangible Assets, Gross (Excluding Goodwill) | 16,303 | 13,011 |
Finite-Lived Intangible Assets, Accumulated Amortization | (5,179) | (4,697) |
Intangible Assets, Net (Excluding Goodwill) | 11,124 | 8,314 |
Trademarks and Technology [Member] | ||
Intangible Assets [Line Items] | ||
Intangible Assets, Gross (Excluding Goodwill) | 2,398 | 1,630 |
Finite-Lived Intangible Assets, Accumulated Amortization | (704) | (739) |
Intangible Assets, Net (Excluding Goodwill) | 1,694 | 891 |
Trademarks and Trade Names [Member] | ||
Intangible Assets [Line Items] | ||
Intangible Assets, Gross (Excluding Goodwill) | 661 | 617 |
Finite-Lived Intangible Assets, Accumulated Amortization | 0 | 0 |
Intangible Assets, Net (Excluding Goodwill) | 661 | 617 |
Other Intangible Assets [Member] | ||
Intangible Assets [Line Items] | ||
Intangible Assets, Gross (Excluding Goodwill) | 1,176 | 422 |
Finite-Lived Intangible Assets, Accumulated Amortization | (254) | (200) |
Intangible Assets, Net (Excluding Goodwill) | $ 922 | $ 222 |
Goodwill and Intangible Asset_6
Goodwill and Intangible Assets Weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 5,761 | $ 660 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | 8 years |
Customer-Related Intangible Assets [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 3,927 | $ 484 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 15 years | 9 years |
Trademarks and Technology [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 1,058 | $ 147 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years | 5 years |
Other Intangible Assets [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 776 | $ 29 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | 11 years |
Goodwill and Intangible Asset_7
Goodwill and Intangible Assets Amortization Expense relating to Intangible Assets (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Finite-Lived Intangible Assets [Line Items] | |
2023 | $ 1,562 |
2024 | 1,478 |
2025 | 1,360 |
2026 | 1,206 |
2027 | $ 1,154 |
Medical Costs Payable (Narrativ
Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions | Dec. 31, 2022 | Dec. 31, 2021 |
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount | $ 20 | $ 17.1 |
Medical Costs Payable Rollforwa
Medical Costs Payable Rollforward (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items] | |||
Medical costs payable, beginning of period | $ 24,483 | $ 21,872 | $ 21,690 |
Acquisitions | 308 | 88 | 316 |
Reported medical costs: | |||
Current year | 211,252 | 188,631 | 160,276 |
Prior years | (410) | (1,720) | (880) |
Total reported medical costs | 210,842 | 186,911 | 159,396 |
Medical payments: | |||
Payments for current year | (184,049) | (165,524) | (139,974) |
Payments for prior years | (22,528) | (18,864) | (19,556) |
Total medical payments | (206,577) | (184,388) | (159,530) |
Medical costs payable, end of period | $ 29,056 | $ 24,483 | $ 21,872 |
Medical Costs Payable, Incurred
Medical Costs Payable, Incurred and Paid Medical Cost Development (Details) - Health Insurance Product Line [Member] - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Net Incurred Medical Costs | $ 399,659 | |
Net Cumulative Medical Payments | (370,993) | |
Net remaining outstanding liabilities prior to 2021 | 390 | |
Total Medical costs payable | 29,056 | |
Short-duration Insurance Contracts, Accident Year 2021 [Member] | ||
Net Incurred Medical Costs | 188,407 | $ 188,631 |
Net Cumulative Medical Payments | (186,944) | $ (165,524) |
Short-duration Insurance Contracts, Accident Year 2022 [Member] | ||
Net Incurred Medical Costs | 211,252 | |
Net Cumulative Medical Payments | $ (184,049) |
Short-Term Borrowings and Lon_3
Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Minimum [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate During Period | 5.10% | |
Maximum [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Interest Rate During Period | 7.50% | |
364 Day $6.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 6,000 | |
Line of Credit Facility, Expiration Period | 364 days | |
Three Year $6.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 6,000 | |
Line of Credit Facility, Expiration Period | 3 years | |
Five Year $6.0 Billion Credit Facility [Member] | Revolving Credit Facility [Member] | ||
Debt Instrument [Line Items] | ||
Line of Credit, Credit Facility, Maximum Borrowing Capacity | $ 6,000 | |
Line of Credit Facility, Expiration Period | 5 years | |
Subsidiaries [Member] | ||
Debt Instrument [Line Items] | ||
Other Long-term Debt | $ 900 | $ 1,400 |
Other Long-term Debt, Current | $ 192 | $ 611 |
Short-Term Borrowings and Lon_4
Short-Term Borrowings and Long-Term Debt (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Debt Instrument [Line Items] | ||
Carrying Value | $ 56,756 | $ 44,632 |
Commercial Paper [Member] | ||
Debt Instrument [Line Items] | ||
Commercial Paper | 800 | 0 |
2.875% Notes Due March 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,100 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Unsecured Debt, Current | $ 0 | 1,097 |
3.350% Notes Due July 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.35% | |
Unsecured Debt, Current | $ 0 | 999 |
2.375% notes due October 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 900 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.375% | |
Unsecured Debt, Current | $ 0 | 899 |
0.000% Notes Due November 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 15 | |
Debt Instrument, Interest Rate, Stated Percentage | 0% | |
Unsecured Debt, Current | $ 0 | 14 |
2.750% Notes Due February 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 625 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |
Unsecured Debt, Current | $ 622 | |
Unsecured Long-term Debt, Noncurrent | 632 | |
2.875% Notes Due March 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Unsecured Debt, Current | $ 746 | |
Unsecured Long-term Debt, Noncurrent | 768 | |
3.500% notes due June 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Unsecured Debt, Current | $ 750 | |
Unsecured Long-term Debt, Noncurrent | 749 | |
3.500% notes due February 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Unsecured Long-term Debt, Noncurrent | $ 749 | 748 |
0.550% notes due May 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 0.55% | |
Unsecured Long-term Debt, Noncurrent | $ 998 | 996 |
2.375% notes due August 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.375% | |
Unsecured Long-term Debt, Noncurrent | $ 749 | 748 |
5.000% notes due October 2024 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 500 | |
Debt Instrument, Interest Rate, Stated Percentage | 5% | |
Unsecured Long-term Debt, Noncurrent | $ 499 | 0 |
3.750% Notes Due July 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Unsecured Long-term Debt, Noncurrent | $ 1,995 | 1,994 |
5.150% notes due October 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.15% | |
Unsecured Long-term Debt, Noncurrent | $ 747 | 0 |
3.700% notes due December 2025 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 300 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Unsecured Long-term Debt, Noncurrent | $ 299 | 299 |
1.250% notes due January 2026 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 500 | |
Debt Instrument, Interest Rate, Stated Percentage | 1.25% | |
Unsecured Long-term Debt, Noncurrent | $ 498 | 497 |
3.100% notes due March 2026 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.10% | |
Unsecured Long-term Debt, Noncurrent | $ 998 | 997 |
1.150% notes due May 2026 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 1.15% | |
Unsecured Long-term Debt, Noncurrent | $ 893 | 972 |
3.450% notes due January 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.45% | |
Unsecured Long-term Debt, Noncurrent | $ 748 | 747 |
3.375% notes due April 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 625 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.375% | |
Unsecured Long-term Debt, Noncurrent | $ 622 | 621 |
3.700% notes due May 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 600 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Unsecured Long-term Debt, Noncurrent | $ 597 | 0 |
2.950% notes due October 2027 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 950 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.95% | |
Unsecured Long-term Debt, Noncurrent | $ 943 | 942 |
5.250% notes due February 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.25% | |
Unsecured Long-term Debt, Noncurrent | $ 1,008 | 0 |
3.850% notes due June 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,150 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.85% | |
Unsecured Long-term Debt, Noncurrent | $ 1,145 | 1,144 |
3.875% notes due December 2028 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 850 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Unsecured Long-term Debt, Noncurrent | $ 845 | 844 |
4.000% notes due May 2029 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 900 | |
Debt Instrument, Interest Rate, Stated Percentage | 4% | |
Unsecured Long-term Debt, Noncurrent | $ 849 | 0 |
2.875% notes due August 2029 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.875% | |
Unsecured Long-term Debt, Noncurrent | $ 886 | 1,023 |
5.300% notes due February 2030 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.30% | |
Unsecured Long-term Debt, Noncurrent | $ 1,269 | 0 |
2.000% notes due May 2030 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 2% | |
Unsecured Long-term Debt, Noncurrent | $ 1,237 | 1,235 |
2.300% notes due May 2031 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,500 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.30% | |
Unsecured Long-term Debt, Noncurrent | $ 1,256 | 1,482 |
4.200% notes due May 2032 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,500 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.20% | |
Unsecured Long-term Debt, Noncurrent | $ 1,393 | 0 |
5.350% notes due February 2033 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.35% | |
Unsecured Long-term Debt, Noncurrent | $ 2,037 | 0 |
4.625% notes Due July 2035 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Unsecured Long-term Debt, Noncurrent | $ 993 | 993 |
5.800% notes Due March 2036 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 850 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.80% | |
Unsecured Long-term Debt, Noncurrent | $ 840 | 839 |
6.500% notes Due June 2037 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 500 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | |
Unsecured Long-term Debt, Noncurrent | $ 493 | 492 |
6.625% notes due November 2037 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 650 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.625% | |
Unsecured Long-term Debt, Noncurrent | $ 642 | 642 |
6.875% notes Due Februray 2038 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,100 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.875% | |
Unsecured Long-term Debt, Noncurrent | $ 1,079 | 1,078 |
3.500% notes due August 2039 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.50% | |
Unsecured Long-term Debt, Noncurrent | $ 1,242 | 1,242 |
2.750% notes due May 2040 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | |
Unsecured Long-term Debt, Noncurrent | $ 967 | 966 |
5.700% notes Due October 2040 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 300 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.70% | |
Unsecured Long-term Debt, Noncurrent | $ 296 | 296 |
5.950% notes Due Februrary 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 350 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.95% | |
Unsecured Long-term Debt, Noncurrent | $ 346 | 346 |
3.050% notes due May 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,500 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.05% | |
Unsecured Long-term Debt, Noncurrent | $ 1,483 | 1,483 |
4.625% notes Due November 2041 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 600 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.625% | |
Unsecured Long-term Debt, Noncurrent | $ 590 | 589 |
4.375% notes Due March 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 502 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.375% | |
Unsecured Long-term Debt, Noncurrent | $ 486 | 485 |
3.950% notes Due October 2042 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 625 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.95% | |
Unsecured Long-term Debt, Noncurrent | $ 609 | 608 |
4.250% notes Due March 2043 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Unsecured Long-term Debt, Noncurrent | $ 736 | 736 |
4.750% notes Due July 2045 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.75% | |
Unsecured Long-term Debt, Noncurrent | $ 1,975 | 1,974 |
4.200% notes due January 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 750 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.20% | |
Unsecured Long-term Debt, Noncurrent | $ 739 | 739 |
4.250% notes due April 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 725 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Unsecured Long-term Debt, Noncurrent | $ 718 | 718 |
3.750% notes due October 2047 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 950 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.75% | |
Unsecured Long-term Debt, Noncurrent | $ 935 | 934 |
4.250% notes due June 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,350 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.25% | |
Unsecured Long-term Debt, Noncurrent | $ 1,331 | 1,330 |
4.450% notes due December 2048 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,100 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.45% | |
Unsecured Long-term Debt, Noncurrent | $ 1,087 | 1,087 |
3.700% notes due August 2049 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.70% | |
Unsecured Long-term Debt, Noncurrent | $ 1,236 | 1,236 |
2.900% notes due May 2050 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.90% | |
Unsecured Long-term Debt, Noncurrent | $ 1,210 | 1,209 |
3.250% notes due May 2051 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.25% | |
Unsecured Long-term Debt, Noncurrent | $ 1,971 | 1,970 |
4.750% notes due May 2052 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.75% | |
Unsecured Long-term Debt, Noncurrent | $ 1,965 | 0 |
5.875% notes due February 2053 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 2,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 5.875% | |
Unsecured Long-term Debt, Noncurrent | $ 1,968 | 0 |
3.875% notes due August 2059 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,250 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.875% | |
Unsecured Long-term Debt, Noncurrent | $ 1,228 | 1,228 |
3.125% notes due May 2060 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 3.125% | |
Unsecured Long-term Debt, Noncurrent | $ 966 | 965 |
4.950% notes due May 2062 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,000 | |
Debt Instrument, Interest Rate, Stated Percentage | 4.95% | |
Unsecured Long-term Debt, Noncurrent | $ 981 | 0 |
6.050% notes due February 2063 [Member] | ||
Debt Instrument [Line Items] | ||
Par Value | $ 1,500 | |
Debt Instrument, Interest Rate, Stated Percentage | 6.05% | |
Unsecured Long-term Debt, Noncurrent | $ 1,466 | $ 0 |
Short-Term Borrowings and Lon_5
Short-Term Borrowings and Long-Term Debt Maturities of commercial paper and long-term debt (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Debt Instrument [Line Items] | |
2023 | $ 3,117 |
2024 | 3,136 |
2025 | 3,186 |
2026 | 2,636 |
2027 | 3,061 |
Thereafter | $ 43,638 |
Income Taxes (Narrative) (Detai
Income Taxes (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Contingency [Line Items] | |||
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | $ 64 | $ 66 | $ 52 |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | 253 | $ 194 | |
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit | 260 | ||
Unrecognized Tax Benefits that Would Impact Effective Tax Rate | $ 1,700 | ||
Federal [Member] | Earliest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Jan. 01, 2023 | ||
Open Tax Year | 2017 | ||
Federal [Member] | Latest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Jan. 01, 2037 | ||
Open Tax Year | 2020 | ||
State [Member] | Earliest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Jan. 01, 2023 | ||
Open Tax Year | 2014 | ||
State [Member] | Latest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Tax Credit Carryforward, Expiration Date | Jan. 01, 2042 | ||
Open Tax Year | 2022 | ||
Non-U.S [Member] | Earliest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Open Tax Year | 2015 | ||
Non-U.S [Member] | Latest Tax Year [Member] | |||
Income Tax Contingency [Line Items] | |||
Open Tax Year | 2022 | ||
Finite-lived NOL carryforwards [Member] | Federal [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | $ 490 | ||
Indefinite NOL carryforwards [Member] | Federal [Member] | |||
Income Tax Contingency [Line Items] | |||
Operating Loss Carryforwards | $ 611 |
Income Taxes Reconciliation of
Income Taxes Reconciliation of Provision for Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Current Provision: | |||
Federal | $ 4,842 | $ 3,451 | $ 4,098 |
State and local | 855 | 481 | 392 |
Foreign | 680 | 516 | 491 |
Total current provision | 6,377 | 4,448 | 4,981 |
Deferred (benefit) provision | (673) | 130 | (8) |
Total provision for income taxes | $ 5,704 | $ 4,578 | $ 4,973 |
Income Tax Reconciliation of th
Income Tax Reconciliation of the tax provision at the U.S. Federal Statutory Rate (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Contingency [Line Items] | |||
Tax provision at the U.S. federal statutory rate, Amount | $ 5,532 | $ 4,685 | $ 4,356 |
Tax provision at the U.S. federal statutory rate, Percent | 21% | 21% | 21% |
State income taxes, net of federal benefit, Amount | $ 621 | $ 419 | $ 315 |
State income taxes, net of federal benefit, Percent | 2.40% | 1.90% | 1.50% |
Share-based awards - excess tax benefit, Amount | $ (110) | $ (100) | $ (130) |
Share-based awards - excess tax benefit, Percent | (0.40%) | (0.40%) | (0.60%) |
Non-deductible compensation, Amount | $ 150 | $ 144 | $ 134 |
Non-deductible compensation, Percent | 0.60% | 0.60% | 0.70% |
Health insurance industry tax, Amount | $ 0 | $ 0 | $ 626 |
Health insurance industry tax, Percent | 0% | 0% | 3% |
Foreign rate differential, Amount | $ (265) | $ (246) | $ (164) |
Foreign rate differential, Percent | (1.00%) | (1.10%) | (0.80%) |
Other, net, Amount | $ (224) | $ (324) | $ (164) |
Other, net, Percent | (0.90%) | (1.50%) | (0.80%) |
Total provision for income taxes | $ 5,704 | $ 4,578 | $ 4,973 |
Provision for income taxes, Percent | 21.70% | 20.50% | 24% |
Income Taxes Components of Defe
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred income tax assets: | ||
Accrued expenses and allowances | $ 707 | $ 723 |
U.S. federal and state net operating loss carryforwards | 540 | 287 |
Share-based compensation | 154 | 117 |
Nondeductible liabilities | 341 | 296 |
Non-U.S. tax loss carryforwards | 631 | 435 |
Lease liability | 972 | 1,284 |
Net unrealized losses on investments | 829 | 0 |
Other-domestic | 291 | 228 |
Other-non-U.S. | 423 | 376 |
Subtotal | 4,888 | 3,746 |
Less: valuation allowances | (291) | (198) |
Total deferred income tax assets | 4,597 | 3,548 |
Deferred income tax liabilities: | ||
U.S. federal and state intangible assets | (3,520) | (2,658) |
Non-U.S. goodwill and intangible assets | (550) | (512) |
Capitalized software | (548) | (833) |
Depreciation and amortization | (520) | (349) |
Prepaid expenses | (275) | (256) |
Outside basis in partnerships | (653) | (565) |
Lease right-of-use asset | (958) | (1,267) |
Net unrealized gains on investments | 0 | (125) |
Other-non-U.S. | (342) | (248) |
Total deferred income tax liabilities | (7,366) | (6,813) |
Net deferred income tax liabilities | $ (2,769) | $ (3,265) |
Income Taxes Reconciliation o_2
Income Taxes Reconciliation of the beginning and ending amount of unrecognized tax benefits (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Contingency [Line Items] | |||
Gross unrecognized tax benefits, beginning of period | $ 2,310 | $ 1,829 | $ 1,423 |
Current year tax positions | 586 | 538 | 416 |
Prior year tax positions, gross increases | 206 | 10 | 120 |
Prior year tax positions, gross decreases | (21) | (47) | (130) |
Statute of limitations lapses | 0 | (20) | 0 |
Gross unrecognized tax benefits, end of period | $ 3,081 | $ 2,310 | $ 1,829 |
Shareholders' Equity (Narrative
Shareholders' Equity (Narrative) (Details) - USD ($) shares in Millions, $ in Billions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Jun. 01, 2018 | |
Shareholders' Equity Disclosure [Line Items] | |||
Cash Dividends Paid to Parent, Consolidated Subsidiaries | $ 8.8 | $ 8 | |
Statutory Accounting Practices, Statutory Capital and Surplus, Balance | 33.8 | ||
Statutory Accounting Practices, Statutory Capital and Surplus Required | 15.4 | ||
Stock Repurchase Program, Number of Shares Authorized to be Repurchased | 100 | ||
Extraordinary Dividends [Member] | |||
Shareholders' Equity Disclosure [Line Items] | |||
Cash Dividends Paid to Parent, Consolidated Subsidiaries | $ 7.4 | $ 4.7 |
Shareholders' Equity Share Repu
Shareholders' Equity Share Repurchases (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | |||
Common shares repurchases, shares | 14,000,000 | 13,000,000 | |
Common share repurchases, average price per share | $ 501.67 | $ 389.92 | |
Common share repurchases | $ 7,000 | $ 5,000 | $ 4,250 |
Board authorized shares remaining | 31,000,000 | 45,000,000 |
Shareholders' Equity Dividends
Shareholders' Equity Dividends (Details) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||||||
Dec. 13, 2022 | Sep. 20, 2022 | Jun. 28, 2022 | Mar. 22, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | |||||||
Cash dividends per common share | $ 1.65 | $ 1.65 | $ 1.65 | $ 1.45 | $ 6.40 | $ 5.60 | $ 4.83 |
Payments of Ordinary Dividends, Common Stock | $ 1,541 | $ 1,542 | $ 1,545 | $ 1,363 | $ 5,991 | $ 5,280 | $ 4,584 |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) shares in Millions, $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 59 | |
Deferred Compensation, Recorded Liability | $ 1,600 | $ 1,800 |
Employee Stock Purchase Plan (ESPP) [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 18 |
Share-Based Compensation (Stock
Share-Based Compensation (Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended |
Dec. 31, 2022 USD ($) $ / shares shares | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | |
Outstanding at the beginning of the period | shares | 25 |
Granted | shares | 4 |
Exercised | shares | (5) |
Forfeitures | shares | (1) |
Outstanding at the end of the period | shares | 23 |
Exercisable at end of period | shares | 13 |
Vested and expected to vest, end of period | shares | 23 |
Outstanding at beginning of period, Weighted-Average Exercise Price | $ / shares | $ 241 |
Granted, Weighted-Average Exercise Price | $ / shares | 459 |
Exercised, Weighted-Average Exercise Price | $ / shares | 215 |
Forfeitures, Weighted Average Exercise Price | $ / shares | 356 |
Outstanding at end of period, Weighted-Average Exercise Price | $ / shares | 281 |
Exercisable at end of period, Weighted-Average Exercise Price | $ / shares | 213 |
Vested and expected to vest end of period, Weighted-Average Exercise Price | $ / shares | $ 278 |
Outstanding at end of period, Weighted Average Remaining Contractual Term (in years) | 5 years 9 months 18 days |
Exercisable at end of period, Weighted Average Remaining Contractual Term (in years) | 4 years 4 months 25 days |
Vested and expected to vest end of period, Weighted Average Remaining Contractual Term (in years) | 5 years 8 months 13 days |
Outstanding at end of period, Aggregate Intrinsic Value | $ | $ 5,914 |
Exercisable at end of period, Aggregate Intrinsic Value | $ | 4,170 |
Vested and expected to vest end of period, Aggregate Intrinsic Value | $ | $ 5,854 |
Share-Based Compensation (Restr
Share-Based Compensation (Restricted Share Activity) (Details) - Restricted Stock [Member] shares in Millions | 12 Months Ended |
Dec. 31, 2022 $ / shares shares | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Nonvested at beginning of period | shares | 4 |
Granted | shares | 2 |
Vested | shares | (2) |
Nonvested at end of period | shares | 4 |
Nonvested at beginning of period, Weighted-Average Grant Date Fair Value per Share | $ / shares | $ 303 |
Weighted-average grant date fair value per share | $ / shares | 483 |
Vested, Weighted Average Grant Date Fair Value per share | $ / shares | 287 |
Nonvested at end of period, Weighted-Average Grant Date Fair Value per Share | $ / shares | $ 401 |
Share-Based Compensation Other
Share-Based Compensation Other Share-Based Compensation Data (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation expense, before tax | $ 925 | $ 800 | $ 679 |
Share-based compensation expense, net of tax effects | 836 | 719 | 619 |
Income tax benefit realized from share-based award exercises | 207 | $ 173 | $ 208 |
Unrecognized compensation expense related to share awards | $ 1,165 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 3 months 18 days | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant date fair value of shares granted, per share | $ 116 | $ 71 | $ 54 |
Total intrinsic value of stock options exercised | $ 1,419 | $ 1,519 | $ 1,736 |
Restricted Stock Units (RSUs) [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average grant date fair value per share | $ 483 | $ 352 | $ 303 |
Total fair value of restricted shares vested | $ 760 | $ 560 | $ 574 |
Employee Stock Purchase Plan (ESPP) [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares purchased | 1 | 1 | 1 |
Share-Based Compensation (Share
Share-Based Compensation (Share-Based Compensation Principal Fair Value Assumptions) (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Forfeiture rate | 5% | 5% | 5% |
Expected Life in years | 4 years 8 months 13 days | 4 years 9 months 19 days | 5 years 1 month 7 days |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 5 years 9 months 18 days | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | 4 years 4 months 25 days | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term | 5 years 8 months 13 days | ||
Minimum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate | 1.90% | 0.70% | 0.20% |
Expected Volatility | 30.60% | 29.20% | 22.20% |
Expected dividend yield | 1.20% | 1.30% | 1.40% |
Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate | 4.30% | 1.20% | 1.40% |
Expected Volatility | 30.80% | 29.80% | 29.50% |
Expected dividend yield | 1.20% | 1.50% | 1.70% |
Commitments and Contingencies_3
Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Feb. 22, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Loss Contingencies [Line Items] | ||||
Operating Lease, Cost | $ 1,300 | $ 1,200 | $ 1,100 | |
Operating Lease, Payments | $ 996 | $ 921 | $ 865 | |
Operating Lease, Weighted Average Remaining Lease Term | 8 years 7 months 6 days | |||
Operating Lease, Weighted Average Discount Rate, Percent | 3.40% | |||
Other Commitment | $ 9,000 | |||
Other Commitments, Description | As of December 31, 2022, the Company has entered into agreements to acquire companies in the health care sector, most notably, LHC Group, Inc. (NASDAQ: LHCG), subject to regulatory approval and other customary closing conditions. | |||
Subsequent Event [Member] | ||||
Loss Contingencies [Line Items] | ||||
Subsequent Event, Description | The Company completed the acquisition of LHC Group, Inc. on February 22, 2023. |
Commitment and Contingencies Fu
Commitment and Contingencies Future Lease Payments (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Operating Leased Assets [Line Items] | |
2023 | $ 997 |
2024 | 858 |
2025 | 702 |
2026 | 578 |
2027 | 475 |
Thereafter | 2,028 |
Total future minimum lease payments | 5,638 |
Less imputed interest | (808) |
Total | $ 4,830 |
Business Combinations (Narrativ
Business Combinations (Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Oct. 03, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Cash received from dispositions | $ 3,414 | $ 15 | $ 221 | |
Change Healthcare Claim Editing Business | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Cash received from dispositions | 2,200 | |||
Other Dispositions | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Cash received from dispositions | 1,200 | |||
Carrying Value of Disposition | 600 | |||
Change Healthcare | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Business Combination, Consideration Transferred | $ 13,900 | |||
Other Acquisitions | ||||
Business Combination, Separately Recognized Transactions [Line Items] | ||||
Business Combination, Consideration Transferred | $ 8,800 |
Business Combinations Acquired
Business Combinations Acquired Assets and Liabilities (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Business Combination, Separately Recognized Transactions [Line Items] | |||
Goodwill | $ 93,352 | $ 75,795 | $ 71,337 |
Change Healthcare Acquisition | |||
Business Combination, Separately Recognized Transactions [Line Items] | |||
Cash and cash equivalents | 222 | ||
Accounts receivable and other current assets | 925 | ||
Assets held-for-sale | 2,310 | ||
Property, equipment and other long-term assets | 254 | ||
Other intangible assets | 4,050 | ||
Total identifiable assets acquired | 7,761 | ||
Medical costs payable | 0 | ||
Accounts payable and other current liabilities | (1,017) | ||
Liabilities held-for-sale | (101) | ||
Other long-term liabilities | (1,193) | ||
Total identifiable liabilities acquired | (2,311) | ||
Total net identifiable assets | 5,450 | ||
Goodwill | 8,496 | ||
Redeemable noncontrolling interests | 0 | ||
Nonredeemable noncontrolling interests | 0 | ||
Net assets acquired | 13,946 | ||
Other Acquisitions | |||
Business Combination, Separately Recognized Transactions [Line Items] | |||
Cash and cash equivalents | 523 | ||
Accounts receivable and other current assets | 696 | ||
Assets held-for-sale | 0 | ||
Property, equipment and other long-term assets | 1,882 | ||
Other intangible assets | 1,764 | ||
Total identifiable assets acquired | 4,865 | ||
Medical costs payable | (308) | ||
Accounts payable and other current liabilities | (843) | ||
Liabilities held-for-sale | 0 | ||
Other long-term liabilities | (713) | ||
Total identifiable liabilities acquired | (1,864) | ||
Total net identifiable assets | 3,001 | ||
Goodwill | 9,214 | ||
Redeemable noncontrolling interests | 3,108 | ||
Nonredeemable noncontrolling interests | 370 | ||
Net assets acquired | 8,737 | ||
Acquisitions | |||
Business Combination, Separately Recognized Transactions [Line Items] | |||
Cash and cash equivalents | 745 | ||
Accounts receivable and other current assets | 1,621 | ||
Assets held-for-sale | 2,310 | ||
Property, equipment and other long-term assets | 2,136 | ||
Other intangible assets | 5,814 | ||
Total identifiable assets acquired | 12,626 | ||
Medical costs payable | (308) | ||
Accounts payable and other current liabilities | (1,860) | ||
Liabilities held-for-sale | (101) | ||
Other long-term liabilities | (1,906) | ||
Total identifiable liabilities acquired | (4,175) | ||
Total net identifiable assets | 8,451 | ||
Goodwill | 17,710 | ||
Redeemable noncontrolling interests | 3,108 | ||
Nonredeemable noncontrolling interests | 370 | ||
Net assets acquired | $ 22,683 |
Business Combinations Acquire_2
Business Combinations Acquired Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 5,761 | $ 660 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | 8 years |
Change Healthcare | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 4,050 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | |
Other Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 1,711 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | |
Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 5,761 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | |
Customer-Related Intangible Assets [Member] | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 3,927 | $ 484 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 15 years | 9 years |
Customer-Related Intangible Assets [Member] | Change Healthcare | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 3,063 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 15 years | |
Customer-Related Intangible Assets [Member] | Other Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 864 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | |
Customer-Related Intangible Assets [Member] | Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 3,927 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 15 years | |
Trademarks and Technology [Member] | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 1,058 | $ 147 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years | 5 years |
Trademarks and Technology [Member] | Change Healthcare | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 977 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years | |
Trademarks and Technology [Member] | Other Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 81 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 4 years | |
Trademarks and Technology [Member] | Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 1,058 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 6 years | |
Other Intangible Assets [Member] | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 776 | $ 29 |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | 11 years |
Other Intangible Assets [Member] | Change Healthcare | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 10 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 1 year | |
Other Intangible Assets [Member] | Other Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 766 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years | |
Other Intangible Assets [Member] | Acquisitions | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 776 | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 13 years |
Segment Financial Information_3
Segment Financial Information (Narrative) (Details) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement [Line Items] | |||
Number of Reportable Segments | 4 | ||
UNITED STATES | |||
Statement [Line Items] | |||
Disclosure on Geographic Areas Percentage of Revenue from External Customers | 97% | 97% | 97% |
Disclosure on Geographic Areas Percentage of Long Lived Assets | 81% | 78% | |
Revenues [Member] | CMS [Member] | Revenue Benchmark | |||
Statement [Line Items] | |||
Concentration Risk, Percentage | 38% | 36% | 36% |
Segment Financial Information_4
Segment Financial Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | $ 257,157 | $ 226,233 | $ 201,478 |
Investment and other income | 2,030 | 2,324 | 1,502 |
Total revenues | 324,162 | 287,597 | 257,141 |
Earnings from operations | 28,435 | 23,970 | 22,405 |
Interest expense | (2,092) | (1,660) | (1,663) |
Earnings before income taxes | 26,343 | 22,310 | 20,742 |
Total assets | 245,705 | 212,206 | 197,289 |
Purchases of property, equipment and capitalized software | 2,802 | 2,454 | 2,051 |
Depreciation and amortization | 3,400 | 3,103 | 2,891 |
Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 37,424 | 34,437 | 34,145 |
Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 27,551 | 24,603 | 20,016 |
Optum | |||
Statement [Line Items] | |||
Investment and other income | 1,107 | 1,467 | 770 |
Total revenues | 182,768 | 155,565 | 136,308 |
Earnings from operations | 14,056 | 11,995 | 10,046 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 14,056 | 11,995 | 10,046 |
Total assets | 147,516 | 117,523 | 106,778 |
Purchases of property, equipment and capitalized software | 2,003 | 1,659 | 1,364 |
Depreciation and amortization | 2,427 | 2,099 | 1,971 |
Unaffiliated Customers | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 257,157 | 226,233 | 201,478 |
Total revenues | 322,132 | 285,273 | 255,639 |
Unaffiliated Customers | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 37,424 | 34,437 | 34,145 |
Unaffiliated Customers | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 27,551 | 24,603 | 20,016 |
Unaffiliated Customers | Optum | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 18,374 | 13,852 | 9,799 |
Total revenues | 73,314 | 63,231 | 55,496 |
Unaffiliated Customers | Optum | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 37,424 | 34,437 | 34,145 |
Unaffiliated Customers | Optum | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 17,516 | 14,942 | 11,552 |
Affiliated Customers | |||
Statement [Line Items] | |||
Total revenues | 0 | 0 | 0 |
Affiliated Customers | Optum | |||
Statement [Line Items] | |||
Total revenues | 108,347 | 90,867 | 80,042 |
Operating Segments | UnitedHealthcare | |||
Statement [Line Items] | |||
Investment and other income | 923 | 857 | 732 |
Total revenues | 249,741 | 222,899 | 200,875 |
Earnings from operations | 14,379 | 11,975 | 12,359 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 14,379 | 11,975 | 12,359 |
Total assets | 107,094 | 102,967 | 98,229 |
Purchases of property, equipment and capitalized software | 799 | 795 | 687 |
Depreciation and amortization | 973 | 1,004 | 920 |
Operating Segments | Optum Health | |||
Statement [Line Items] | |||
Investment and other income | 928 | 1,053 | 680 |
Total revenues | 71,174 | 54,065 | 39,808 |
Earnings from operations | 6,032 | 4,462 | 3,434 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 6,032 | 4,462 | 3,434 |
Total assets | 68,950 | 60,474 | 52,073 |
Purchases of property, equipment and capitalized software | 997 | 791 | 715 |
Depreciation and amortization | 943 | 818 | 703 |
Operating Segments | Optum Insight | |||
Statement [Line Items] | |||
Investment and other income | 117 | 237 | 39 |
Total revenues | 14,581 | 12,199 | 10,802 |
Earnings from operations | 3,588 | 3,398 | 2,725 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 3,588 | 3,398 | 2,725 |
Total assets | 31,090 | 16,868 | 15,425 |
Purchases of property, equipment and capitalized software | 698 | 567 | 461 |
Depreciation and amortization | 841 | 684 | 670 |
Operating Segments | Optum Rx | |||
Statement [Line Items] | |||
Investment and other income | 62 | 177 | 51 |
Total revenues | 99,773 | 91,314 | 87,498 |
Earnings from operations | 4,436 | 4,135 | 3,887 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 4,436 | 4,135 | 3,887 |
Total assets | 47,476 | 40,181 | 39,280 |
Purchases of property, equipment and capitalized software | 308 | 301 | 188 |
Depreciation and amortization | 643 | 597 | 598 |
Operating Segments | Unaffiliated Customers | UnitedHealthcare | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 238,783 | 212,381 | 191,679 |
Total revenues | 248,818 | 222,042 | 200,143 |
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 0 | 0 | 0 |
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 10,035 | 9,661 | 8,464 |
Operating Segments | Unaffiliated Customers | Optum Health | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 18,374 | 13,852 | 9,799 |
Total revenues | 29,363 | 23,778 | 16,647 |
Operating Segments | Unaffiliated Customers | Optum Health | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 72 | 32 | 33 |
Operating Segments | Unaffiliated Customers | Optum Health | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 10,917 | 9,894 | 6,815 |
Operating Segments | Unaffiliated Customers | Optum Insight | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 0 | 0 | 0 |
Total revenues | 5,176 | 4,095 | 3,822 |
Operating Segments | Unaffiliated Customers | Optum Insight | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 180 | 159 | 135 |
Operating Segments | Unaffiliated Customers | Optum Insight | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 4,996 | 3,936 | 3,687 |
Operating Segments | Unaffiliated Customers | Optum Rx | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 0 | 0 | 0 |
Total revenues | 38,775 | 35,358 | 35,027 |
Operating Segments | Unaffiliated Customers | Optum Rx | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 37,172 | 34,246 | 33,977 |
Operating Segments | Unaffiliated Customers | Optum Rx | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 1,603 | 1,112 | 1,050 |
Operating Segments | Affiliated Customers | UnitedHealthcare | |||
Statement [Line Items] | |||
Total revenues | 0 | 0 | 0 |
Operating Segments | Affiliated Customers | Optum Health | |||
Statement [Line Items] | |||
Total revenues | 40,883 | 29,234 | 22,481 |
Operating Segments | Affiliated Customers | Optum Insight | |||
Statement [Line Items] | |||
Total revenues | 9,288 | 7,867 | 6,941 |
Operating Segments | Affiliated Customers | Optum Rx | |||
Statement [Line Items] | |||
Total revenues | 60,936 | 55,779 | 52,420 |
Optum Eliminations | |||
Statement [Line Items] | |||
Investment and other income | 0 | 0 | 0 |
Total revenues | (2,760) | (2,013) | (1,800) |
Earnings from operations | 0 | 0 | 0 |
Interest expense | 0 | 0 | 0 |
Earnings before income taxes | 0 | 0 | 0 |
Total assets | 0 | 0 | 0 |
Purchases of property, equipment and capitalized software | 0 | 0 | 0 |
Depreciation and amortization | 0 | 0 | 0 |
Optum Eliminations | Unaffiliated Customers | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 0 | 0 | 0 |
Total revenues | 0 | 0 | 0 |
Optum Eliminations | Unaffiliated Customers | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 0 | 0 | 0 |
Optum Eliminations | Unaffiliated Customers | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 0 | 0 | 0 |
Optum Eliminations | Affiliated Customers | |||
Statement [Line Items] | |||
Total revenues | (2,760) | (2,013) | (1,800) |
Corporate and Eliminations | |||
Statement [Line Items] | |||
Investment and other income | 0 | 0 | 0 |
Total revenues | (108,347) | (90,867) | (80,042) |
Earnings from operations | 0 | 0 | 0 |
Interest expense | (2,092) | (1,660) | (1,663) |
Earnings before income taxes | (2,092) | (1,660) | (1,663) |
Total assets | (8,905) | (8,284) | (7,718) |
Purchases of property, equipment and capitalized software | 0 | 0 | 0 |
Depreciation and amortization | 0 | 0 | 0 |
Corporate and Eliminations | Unaffiliated Customers | |||
Statement [Line Items] | |||
Premiums, revenues - unaffiliated customers | 0 | 0 | 0 |
Total revenues | 0 | 0 | 0 |
Corporate and Eliminations | Unaffiliated Customers | Products | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 0 | 0 | 0 |
Corporate and Eliminations | Unaffiliated Customers | Services | |||
Statement [Line Items] | |||
Revenue from Products and Services - unaffiliated customers | 0 | 0 | 0 |
Corporate and Eliminations | Affiliated Customers | |||
Statement [Line Items] | |||
Total revenues | $ (108,347) | $ (90,867) | $ (80,042) |
Schedule I (Details)
Schedule I (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Condensed Financial Statements, Captions [Line Items] | |||
Cash Dividends Paid to Parent, Consolidated Subsidiaries | $ 8,800 | $ 8,000 | |
Parent Company [Member] | |||
Condensed Financial Statements, Captions [Line Items] | |||
Cash Dividends Paid to Parent, Consolidated Subsidiaries | 15,600 | 10,800 | $ 10,000 |
Return of capital to parent company | 1,424 | 245 | $ 943 |
Notes Payable | 8,700 | 8,100 | |
Subsidiaries [Member] | |||
Condensed Financial Statements, Captions [Line Items] | |||
Other Long-term Debt | $ 900 | $ 1,400 |
Schedule I Condensed Balance Sh
Schedule I Condensed Balance Sheets (Details) - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||||
Cash and cash equivalents | $ 23,365 | $ 21,375 | ||
Total current assets | 69,069 | 61,758 | ||
Other assets | 15,027 | 12,526 | ||
Total assets | 245,705 | 212,206 | $ 197,289 | |
Current liabilities: | ||||
Accounts payable and accrued liabilities | 27,715 | 24,643 | ||
Total current liabilities | 89,237 | 78,292 | ||
Long-term debt, less current maturities | 54,513 | 42,383 | ||
Other liabilities | 12,839 | 11,787 | ||
Total liabilities | 159,358 | 135,727 | ||
Commitments and contingencies (Note 4) | ||||
Shareholders’ equity: | ||||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 | ||
Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding | 9 | 10 | ||
Retained earnings | 86,156 | 77,134 | ||
Accumulated other comprehensive loss | (8,393) | (5,384) | ||
Total liabilities and shareholders’ equity | 245,705 | 212,206 | ||
Parent Company [Member] | ||||
Current assets: | ||||
Cash and cash equivalents | 266 | 2,167 | $ 258 | $ 46 |
Other current assets | 753 | 503 | ||
Total current assets | 1,019 | 2,670 | ||
Equity in net assets of subsidiaries | 136,562 | 116,907 | ||
Long-term notes receivable from subsidiaries | 6,201 | 5,680 | ||
Other assets | 504 | 32 | ||
Total assets | 144,286 | 125,289 | ||
Current liabilities: | ||||
Accounts payable and accrued liabilities | 835 | 605 | ||
Current portion of notes payable to subsidiaries | 8,699 | 8,105 | ||
Short-term borrowings and current maturities of long-term debt | 2,918 | 3,009 | ||
Total current liabilities | 12,452 | 11,719 | ||
Long-term debt, less current maturities | 53,838 | 41,623 | ||
Other liabilities | 224 | 187 | ||
Total liabilities | 66,514 | 53,529 | ||
Shareholders’ equity: | ||||
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | 0 | 0 | ||
Common stock, $0.01 par value - 3,000 shares authorized; 934 and 941 issued and outstanding | 9 | 10 | ||
Retained earnings | 86,156 | 77,134 | ||
Accumulated other comprehensive loss | (8,393) | (5,384) | ||
Total UnitedHealth Group shareholders’ equity | 77,772 | 71,760 | ||
Total liabilities and shareholders’ equity | $ 144,286 | $ 125,289 |
Schedule I Balance Sheet Docume
Schedule I Balance Sheet Document (Details) - $ / shares shares in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 934 | 941 |
Common Stock, shares outstanding | 934 | 941 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Parent Company [Member] | ||
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 3,000 | 3,000 |
Common stock, shares issued | 934 | 941 |
Common Stock, shares outstanding | 934 | 941 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10 | 10 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Schedule I Condensed Statement
Schedule I Condensed Statement of Comprehensive Income (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Investment and other income | $ 2,030 | $ 2,324 | $ 1,502 |
Total revenues | 324,162 | 287,597 | 257,141 |
Operating costs: | |||
Interest expense | 2,092 | 1,660 | 1,663 |
Total operating costs | 295,727 | 263,627 | 234,736 |
Benefit for income taxes | 5,704 | 4,578 | 4,973 |
Net earnings | 20,120 | 17,285 | 15,403 |
Other comprehensive loss | (3,009) | (1,570) | (236) |
Comprehensive income | 17,111 | 15,715 | 15,167 |
Parent Company [Member] | |||
Revenues: | |||
Investment and other income | 255 | 494 | 194 |
Total revenues | 255 | 494 | 194 |
Operating costs: | |||
Operating costs | 121 | 40 | 27 |
Interest expense | 2,110 | 1,583 | 1,594 |
Total operating costs | 2,231 | 1,623 | 1,621 |
Loss before income taxes | (1,976) | (1,129) | (1,427) |
Benefit for income taxes | 429 | 231 | 300 |
Loss of parent company | (1,547) | (898) | (1,127) |
Equity in undistributed income of subsidiaries | 21,667 | 18,183 | 16,530 |
Net earnings | 20,120 | 17,285 | 15,403 |
Other comprehensive loss | (3,009) | (1,570) | (236) |
Comprehensive income | $ 17,111 | $ 15,715 | $ 15,167 |
Schedule I Statement of Cash Fl
Schedule I Statement of Cash Flows (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating activities | |||
Cash flows from operating activities | $ 26,206 | $ 22,343 | $ 22,174 |
Investing activities | |||
Cash paid for acquisitions | (21,458) | (4,821) | (7,139) |
Cash received from dispositions | 3,414 | 15 | 221 |
Cash flows used for investing activities | (28,476) | (10,372) | (12,532) |
Financing activities | |||
Common stock repurchases | (7,000) | (5,000) | (4,250) |
Proceeds from common stock issuances | 1,253 | 1,355 | 1,440 |
Proceeds from (repayments of) short-term borrowings, net | 732 | (1,302) | 872 |
Proceeds from issuance of long-term debt | 14,819 | 6,933 | 4,864 |
Repayments of long-term debt | (3,015) | (3,150) | (3,150) |
Other, net | (1,944) | (295) | (459) |
Cash flows from (used for) financing activities | 4,226 | (7,455) | (3,590) |
(Decrease) increase in cash and cash equivalents | 1,990 | 4,454 | 5,936 |
Cash and cash equivalents, beginning of period | 21,375 | ||
Cash and cash equivalents, end of period | 23,365 | 21,375 | |
Supplemental cash flow disclosures | |||
Cash paid for interest | 1,945 | 1,653 | 1,704 |
Cash paid for income taxes | 5,222 | 3,966 | 4,935 |
Parent Company [Member] | |||
Operating activities | |||
Cash flows from operating activities | 14,754 | 11,439 | 8,842 |
Investing activities | |||
Issuances of notes to subsidiaries | (567) | (444) | (628) |
Repayments of notes to subsidiaries | 281 | 37 | 1,089 |
Cash paid for acquisitions | (20,728) | (4,953) | (7,706) |
Return of capital to parent company | 1,424 | 245 | 943 |
Capital contributions to subsidiaries | (570) | (747) | (43) |
Cash received from dispositions | 2,787 | 0 | 143 |
Cash flows used for investing activities | (17,373) | (5,862) | (6,202) |
Financing activities | |||
Common stock repurchases | (7,000) | (5,000) | (4,250) |
Proceeds from common stock issuances | 1,253 | 1,355 | 1,440 |
Cash dividends paid | (5,991) | (5,280) | (4,584) |
Proceeds from (repayments of) short-term borrowings, net | 732 | (1,302) | 872 |
Proceeds from issuance of long-term debt | 14,819 | 6,933 | 4,864 |
Repayments of long-term debt | (3,015) | (3,150) | (3,150) |
Proceeds from notes from subsidiary | 594 | 3,223 | 2,818 |
Other, net | (674) | (447) | (438) |
Cash flows from (used for) financing activities | 718 | (3,668) | (2,428) |
(Decrease) increase in cash and cash equivalents | (1,901) | 1,909 | 212 |
Cash and cash equivalents, beginning of period | 2,167 | 258 | 46 |
Cash and cash equivalents, end of period | 266 | 2,167 | 258 |
Supplemental cash flow disclosures | |||
Cash paid for interest | 1,969 | 1,575 | 1,633 |
Cash paid for income taxes | $ 4,298 | $ 3,050 | $ 4,185 |
Schedule I Maturities of Short-
Schedule I Maturities of Short-Term Borrowings and Long-Term Debt (Details) $ in Millions | Dec. 31, 2022 USD ($) |
Debt Instrument [Line Items] | |
2023 | $ 3,117 |
2024 | 3,136 |
2025 | 3,186 |
2026 | 2,636 |
2027 | 3,061 |
Thereafter | 43,638 |
Parent Company [Member] | |
Debt Instrument [Line Items] | |
2023 | 2,925 |
2024 | 3,000 |
2025 | 3,050 |
2026 | 2,500 |
2027 | 2,925 |
Thereafter | $ 43,502 |